Cronos (CRON) 10-Q 10 May 22 2022 Q1 Quarterly report Financial data

Cover Page

Cover Page - shares	3 Months Ended
	Mar. 31, 2022	May 09, 2022
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2022
Document Transition Report	false
Entity File Number	001-38403
Entity Registrant Name	CRONOS GROUP INC.
Entity Incorporation, State or Country Code	Z4
Entity Address, Address Line One	111 Peter St. Suite 300
Entity Address, City or Town	Toronto
Entity Address, State or Province	ON
Entity Address, Postal Zip Code	M5V 2H1
City Area Code	416
Local Phone Number	504-0004
Title of 12(b) Security	Common Shares, no par value
Trading Symbol	CRON
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding (in shares)		375,579,171
Amendment Flag	false
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q1
Entity Central Index Key	0001656472
Current Fiscal Year End Date	--12-31

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Current assets
Cash and cash equivalents	$ 861,535	$ 886,973
Short-term investments	119,933	117,684
Accounts receivable, net	25,814	22,067
Other receivables	3,297	5,765
Current portion of loans receivable, net	6,235	5,460
Inventory, net	37,054	32,802
Prepaids and other current assets	9,537	8,967
Total current assets	1,063,405	1,079,718
Investments in equity accounted investees, net	17,084	16,764
Other investments	111,761	118,392
Non-current portion of loans receivable, net	81,529	80,635
Property, plant and equipment, net	71,828	74,070
Right-of-use assets	6,325	8,882
Goodwill	1,119	1,098
Intangible assets, net	17,880	18,079
Other assets	70	100
Total assets	1,371,001	1,397,738
Current liabilities
Accounts payable	10,904	11,218
Accrued liabilities	23,076	26,069
Current portion of lease obligation	2,173	2,711
Derivative liabilities	4,099	14,375
Total current liabilities	40,252	54,373
Due to non-controlling interests	1,888	1,913
Non-current portion of lease obligation	7,094	7,095
Deferred income tax liability	396	81
Total liabilities	49,630	63,462
Shareholders’ equity
Share capital (authorized for issue as of March 31, 2022 and December 31, 2021: unlimited; shares outstanding as of March 31, 2022 and December 31, 2021: 375,299,980 and 374,952,693, respectively)	596,368	595,497
Additional paid-in capital	35,365	32,465
Retained earnings	626,778	659,416
Accumulated other comprehensive income	66,088	49,865
Total equity attributable to shareholders of Cronos Group	1,324,599	1,337,243
Non-controlling interests	(3,228)	(2,967)
Total shareholders’ equity	1,321,371	1,334,276
Total liabilities and shareholders’ equity	$ 1,371,001	$ 1,397,738

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheet (Parenthetical) - shares	Mar. 31, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Common stock, shares issued (in shares)	375,299,980	374,952,693
Common stock, shares outstanding (in shares)	375,299,980	374,952,693

Condensed Consolidated Statemen

Condensed Consolidated Statements of Net Income (Loss) and Comprehensive Income (Loss) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Income Statement [Abstract]
Net revenue, before excise taxes	$ 29,406	$ 14,654
Excise taxes	(4,373)	(2,043)
Net revenue	25,033	12,611
Cost of sales	18,107	15,574
Gross profit	6,926	(2,963)
Operating expenses
Sales and marketing	5,012	10,254
Research and development	4,039	5,102
General and administrative	22,368	21,906
Restructuring costs	3,084	0
Share-based compensation	3,686	2,499
Depreciation and amortization	1,293	735
Impairment loss on long-lived assets	3,493	1,741
Total operating expenses	42,975	42,237
Operating loss	(36,049)	(45,200)
Other income (expense)
Interest income, net	2,046	2,329
Gain (loss) on revaluation of derivative liabilities	10,419	(116,874)
Share of loss from equity accounted investments	0	(1,643)
Gain (loss) on revaluation of financial instruments	4,268	(200)
Impairment loss on other investments	(11,238)	0
Foreign currency transaction loss	(1,872)	0
Other, net	135	(16)
Total other income (expense)	3,758	(116,404)
Loss before income taxes	(32,291)	(161,604)
Income tax expense	362	0
Loss from continuing operations	(32,653)	(161,604)
Loss from discontinued operations	0	(21)
Net loss	(32,653)	(161,625)
Net loss attributable to non-controlling interest	(15)	(313)
Net loss attributable to Cronos Group	(32,638)	(161,312)
Comprehensive loss
Net loss	(32,653)	(161,625)
Other comprehensive income
Foreign exchange gain on translation	15,977	16,284
Comprehensive loss	(16,676)	(145,341)
Comprehensive income (loss) attributable to non-controlling interests	(261)	826
Comprehensive loss attributable to Cronos Group	$ (16,415)	$ (146,167)
Net loss from continuing operations per share
Basic - continuing operations (in dollars per share)	$ (0.09)	$ (0.44)
Diluted - continuing operations (in dollars per share)	$ (0.09)	$ (0.44)
Weighted average number of outstanding shares
Basic (in shares)	375,022,724	363,012,740
Diluted (in shares)	375,022,724	363,012,740

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Equity - USD ($) $ in Thousands	Total	Share capital	Additional paid-in capital	Retained earnings	Accumulated other comprehensive income (loss)	Non-controlling interests
Beginning balance (in shares) at Dec. 31, 2020		360,253,332
Beginning balance at Dec. 31, 2020	$ 1,708,168	$ 569,260	$ 34,596	$ 1,064,509	$ 42,999	$ (3,196)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Activities relating to share-based compensation (in shares)		11,403,258
Activities relating to share-based compensation	5,452	$ 15,652	(2,506)	(7,694)
Net loss	(161,625)			(161,312)		(313)
Foreign exchange gain (loss) on translation	16,284				15,145	1,139
Ending balance (in shares) at Mar. 31, 2021		371,656,590
Ending balance at Mar. 31, 2021	$ 1,568,279	$ 584,912	32,090	895,503	58,144	(2,370)
Beginning balance (in shares) at Dec. 31, 2021	374,952,693	374,952,693
Beginning balance at Dec. 31, 2021	$ 1,334,276	$ 595,497	32,465	659,416	49,865	(2,967)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Activities relating to share-based compensation (in shares)		347,287
Activities relating to share-based compensation	3,771	$ 871	2,900
Net loss	(32,653)			(32,638)		(15)
Foreign exchange gain (loss) on translation	$ 15,977				16,223	(246)
Ending balance (in shares) at Mar. 31, 2022	375,299,980	375,299,980
Ending balance at Mar. 31, 2022	$ 1,321,371	$ 596,368	$ 35,365	$ 626,778	$ 66,088	$ (3,228)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Operating activities
Net loss	$ (32,653)	$ (161,625)
Adjustments to reconcile net loss to cash used in operating activities:
Share-based compensation	3,686	2,499
Depreciation and amortization	2,824	1,880
Impairment loss on long-lived assets	3,493	1,741
Impairment loss on other investments	11,238	0
Share of loss from investments in equity accounted investees	0	1,643
Gain (loss) on revaluation of derivative liabilities	(10,419)	116,874
Expected credit losses on long-term financial assets	0	416
Foreign currency transaction loss	1,872	0
Other non-cash operating activities, net	(4,467)	106
Changes in operating assets and liabilities:
Accounts receivable, net	(3,530)	1,931
Other receivables	2,435	5,687
Prepaids and other current assets	(1,195)	(3,737)
Inventory	(3,867)	(742)
Accounts payable	(178)	(3,119)
Accrued liabilities	(3,150)	(10,169)
Cash flows used in operating activities	(33,911)	(46,615)
Investing activities
Proceeds from dissolution of joint venture	44	0
Proceeds from repayment of loans receivable	790	0
Purchase of property, plant and equipment	(711)	(6,680)
Purchase of intangible assets	(23)	(392)
Advances on loans receivable	0	(2,645)
Cash flows provided by (used in) investing activities	100	(9,717)
Financing activities
Withholding taxes paid on share-based awards	(534)	(8,673)
Other financing activities, net	70	10
Cash flows used in financing activities	(464)	(8,663)
Effect of foreign currency translation on cash and cash equivalents	8,837	11,422
Net change in cash and cash equivalents	(25,438)	(53,573)
Cash and cash equivalents, beginning of period	886,973	1,078,023	$ 1,078,023
Cash and cash equivalents, end of period	861,535	1,024,450	$ 886,973
Supplemental cash flow information
Interest received	822	1,157
Income taxes paid	$ 66	$ 624

Background, Basis of Presentati

Background, Basis of Presentation and Accounting Policies	3 Months Ended
	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Background, Basis of Presentation and Accounting Policies	Background, Basis of Presentation and Accounting Policies (a) Background Cronos Group Inc. (“Cronos Group” or the “Company”) is incorporated in the province of British Columbia and under the Business Corporations Act (British Columbia) with principal executive offices at 111 Peter St., Suite 300, Toronto, Ontario, M5V 2H1. The Company’s common shares are currently listed on the Toronto Stock Exchange (“TSX”) and Nasdaq Global Market (“Nasdaq”) under the ticker symbol “CRON.” Cronos Group is an innovative global cannabinoid company committed to building disruptive intellectual property by advancing cannabis research, technology and product development and is seeking to build an iconic brand portfolio. Cronos Group’s diverse international brand portfolio includes Spinach ® , PEACE NATURALS ® , Lord Jones ® , Happy Dance ® and PEACE+™. (b) Basis of presentation The interim condensed consolidated financial statements of Cronos Group are unaudited. They have been prepared in accordance with Generally Accepted Accounting Principles in the United States (“U.S. GAAP”) for interim financial information and with applicable rules and regulations of the U.S. Securities and Exchange Commission relating to interim financial statements. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2022 are not necessarily indicative of the results that may be expected for any other reporting period. These condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and related notes included in its Annual Report on Form 10-K for the year ended December 31, 2021 (the “Annual Report”). Certain prior year amounts have been reclassified to conform to the current year presentation of our condensed consolidated financial statements. These reclassifications had no effect on the reported results of operations and ending shareholders’ equity. (c) Concentration of risk Credit risk is the risk of financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations. The Company is exposed to credit risk from its operating activities, primarily accounts receivable and other receivables, and its investing activities, including cash held with banks and financial institutions, short-term investments, loans receivable, and advances to joint ventures. The Company’s maximum exposure to this risk is equal to the carrying amount of these financial assets, which amounted to $1,098,413 and $1,118,684 as of March 31, 2022 and December 31, 2021, respectively. An impairment analysis is performed at each reporting date using a provision matrix to measure expected credit losses. The provision rates are based on the days past due for groupings of various customer segments with similar loss patterns. The calculation reflects the probability-weighted outcome, the time value of money and reasonable and supportable information that is available at the reporting date about past events, current conditions and forecasts of future economic conditions. Accounts receivable are written off when there is no reasonable expectation of recovery. Indicators that there is no reasonable expectation of recovery include, amongst others, the failure of a debtor to engage in a repayment plan and a failure to make contractual payments for a period of greater than 120 days past due. As of March 31, 2022 and December 31, 2021, the Company had $9 and $8, respectively, in expected credit losses that have been recognized on receivables from contracts with customers in the Rest of World (“ROW”) segment. As of March 31, 2022 and December 31, 2021, the Company had $138 and $104, respectively, in expected credit losses that have been recognized on receivables from contracts with customers in the United States (“U.S.”) segment. As of March 31, 2022, the Company assessed that there is a concentration of credit risk, as 72% of the Company’s accounts receivable were due from three customers with an established credit history with the Company. As of December 31, 2021, 88% of the Company’s accounts receivable were due from four customers with an established credit history with the Company. The Company sells products to a limited number of major customers. Major customers are defined as customers that each individually accounted for greater than 10% of the Company’s revenue. During the three months ended March 31, 2022, the Company earned a total net revenue before excise taxes of $9,833 from two major customers in the ROW segment, together accounting for 33% of the Company’s total net revenue before excise taxes. During the three months ended March 31, 2021, the Rest of World segment earned a total net revenue before excise taxes of $8,963 from four major customers, together accounting for 61% of the Company’s total net revenues before excise taxes. During the three months ended March 31, 2022 and 2021, the U.S. segment had no major customers. (d) Segment information Segment reporting is prepared on the same basis that the Company’s chief operating decision makers (the “CODMs”) manage the business, make operating decisions and assess the Company’s performance. The Company determined that it has the following two reportable segments: U.S. (the “U.S. segment”) and ROW (the “ROW segment”). The U.S. operating segment consists of the manufacture and distribution of U.S. hemp-derived cannabinoid infused products. The ROW operating segment is involved in the cultivation, manufacture, and marketing of cannabis and cannabis-derived products for the medical and adult-use markets . These two segments represent the geographic regions in which the Company operates and the different product offerings within each geographic region. The results of each segment are regularly reviewed by the CODMs to assess the performance of the segment and make decisions regarding the allocation of resources using Adjusted EBITDA (as defined below) as the measure of segment profit or loss. Adjusted EBITDA is defined as earnings before interest, tax, depreciation, non-cash items and items that do not reflect management’s assessment of ongoing business performance. (e) Adoption of new accounting pronouncements On January 1, 2022, the Company adopted ASU No. 2020-06, Debt –Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815–40) (“ASU No. 2020-06”). ASU No. 2020-06 simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. ASU No. 2020-06 is part of the FASB’s simplification initiative, which aims to reduce unnecessary complexity in U.S. GAAP. The adoption of ASU No. 2020-06 did not have an impact on the Company’s interim condensed consolidated financial statements. (f) New accounting pronouncements not yet adopted In March 2022, the FASB issued ASU 2022-02, Financial Instruments – Credit Losses (Topic 326) (“ASU No. 2022-02”). ASU No. 2022-02 eliminates the existing troubled debt restructuring recognition and measurement guidance, and instead aligns the accounting treatment to that of other loan modifications. The amendments enhance existing disclosure requirements and introduce new requirements related to certain modifications of receivables made to borrowers experiencing financial difficulty. ASU No. 2022-02 also requires that entities disclose current-period gross write-offs by year of origination for financing receivables and net investments in leases. ASU No. 2022-02 is effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years, and is to be adopted prospectively. The Company does not expect the adoption of ASU No. 2022-02 to have a material impact on its condensed consolidated financial statements.

Inventory, net

Inventory, net	3 Months Ended
	Mar. 31, 2022
Inventory Disclosure [Abstract]
Inventory, net	Inventory, net Inventory, net is comprised of the following items: As of March 31, 2022 As of December 31, 2021 Raw materials $ 8,523 $ 9,211 Work-in-progress 12,353 12,405 Finished goods 15,587 10,778 Supplies and consumables 591 408 Total $ 37,054 $ 32,802

Investments

Investments	3 Months Ended
	Mar. 31, 2022
Equity Method Investments and Joint Ventures [Abstract]
Investments	Investments (a) Variable interest entities and investments in equity accounted investees, net A reconciliation of the carrying amount of the investments in equity method investees, net is as follows: Ownership interest As of March 31, 2022 As of December 31, 2021 Cronos Growing Company Inc. (“Cronos GrowCo”) 50% $ 17,084 $ 16,764 NatuEra S.à.r.l. (“Natuera”) 50% — — $ 17,084 $ 16,764 The following is a summary of the Company’s share of net losses from equity investments accounted for under the equity method of accounting: For the three months ended March 31, 2022 2021 Cronos GrowCo $ — $ (299) Natuera — (1,344) $ — $ (1,643) (b) Other investments Other investments consist of investments in common shares and options of two companies in the cannabis industry. PharmaCann, Inc. In 2021, the Company purchased an option (the “PharmaCann Option”) to acquire 473,787 shares of Class A Common Stock of PharmaCann Inc. (“PharmaCann”), a vertically integrated cannabis company in the United States, which represented an ownership interest of approximately 10.5% as of December 31, 2021. The PharmaCann Option is classified as an equity security without a readily determinable fair value. The Company has elected to measure the fair value of the PharmaCann Option at cost less impairment, if any, and subsequently adjusted for observable price changes in orderly transactions for the identical or a similar investment of the same issuer. On February 28, 2022, PharmaCann closed the previously announced transaction with LivWell Holdings, Inc. (“LivWell”) pursuant to which PharmaCann acquired LivWell (the “LivWell Transaction”). LivWell is a multi-state cannabis cultivation and retail leader based in Colorado. As a result of the LivWell Transaction, the Company’s ownership percentage in PharmaCann on a fully-diluted basis decreased to approximately 6.4%. The decrease in ownership percentage does not materially affect the Company’s rights under the PharmaCann Option. During the three months ended March 31, 2022, the Company identified indicators of impairment related to the PharmaCann Option and conducted an analysis comparing the PharmaCann Option’s carrying amount to its estimated fair value. The fair value was estimated using a combination of the market and income approaches. Under the income approach, significant inputs used in the discounted cash flow method include discount rate, growth rates, and cash flow projections. As a result of this analysis, the Company recorded a non-cash impairment charge of $11,238, as the difference between the carrying amount of the PharmaCann Option and its estimated fair value in the condensed consolidated statements of net income (loss) and comprehensive income (loss). Cronos Australia Limited The Company owns approximately 10% of the outstanding common shares of Cronos Australia Limited (“Cronos Australia”). The investment is considered an equity security with a readily determinable fair value. Changes in the fair value of the investment are recorded as gain (loss) on revaluation of financial instruments on the condensed consolidated statements of net income (loss) and comprehensive income (loss). The following table summarizes the Company’s other investments activity: As of December 31, 2021 Unrealized gain Impairment charges Foreign exchange effect As of March 31, 2022 PharmaCann $ 110,392 $ — $ (11,238) $ — $ 99,154 Cronos Australia 8,000 4,196 — 411 12,607 $ 118,392 $ 4,196 $ (11,238) $ 411 $ 111,761 During the three months ended March 31, 2021, the Company had no gain or loss on revaluation of other investments. As of March 31, 2022 and December 31, 2021, the Company did not hold any additional other investments.

Loans Receivable, net

Loans Receivable, net	3 Months Ended
	Mar. 31, 2022
Receivables [Abstract]
Loans Receivable, net	Loans Receivable, net Loans receivable, net consists of the following: As of March 31, 2022 As of December 31, 2021 GrowCo Facility (i) $ 3,198 $ 3,138 Add: Current portion of accrued interest 3,037 2,322 Total current portion of loans receivable 6,235 5,460 GrowCo Facility (i) 64,801 64,367 Mucci Promissory Note 14,414 14,019 Cannasoul Collaboration Loan (ii) 2,192 2,249 Add: Long-term portion of accrued interest 122 — Total long-term portion of loans receivable 81,529 80,635 Total loans receivable, net $ 87,764 $ 86,095 (i) On August 23, 2019, the Company, as lender, and Cronos GrowCo, as borrower, entered into a senior secured credit agreement for an aggregate principal amount of C$100,000 (the “GrowCo Facility”). In August 2021, the GrowCo Facility was amended to increase the aggregate principal amount available to C$105,000. As of March 31, 2022 and December 31, 2021, Cronos GrowCo had outstanding borrowings of C$103,000 ($82,354) and C$104,000 ($81,598), respectively, from the GrowCo Facility. As of March 31, 2022, Cronos GrowCo had repaid C$1,000 ($800) under the terms of the GrowCo Facility. The available borrowing capacity under the GrowCo Facility was C$1,000 ($800) at March 31, 2022 and December 31, 2021. (ii) As of March 31, 2022 and December 31, 2021, CLS has received ILS 8,297 ($2,600) and ILS 8,297 ($2,664), respectively, from the Cannasoul Collaboration Loan. Expected credit loss allowances on the Company’s long-term financial assets was comprised of the following items: As of January 1, 2022 Increase (decrease) (i) Foreign exchange effect As of March 31, 2022 GrowCo Facility $ 14,089 $ (4) $ 269 $ 14,354 Mucci Promissory Note 90 1 2 93 Cannasoul Collaboration Loan 415 3 (9) 409 $ 14,594 $ — $ 262 $ 14,856 As of January 1, 2021 Increase (decrease) (i) Foreign exchange effect As of March 31, 2021 GrowCo Facility $ 1,546 $ — $ 23 $ 1,569 Natuera Series A Loan (ii) 721 416 14 1,151 Mucci Promissory Note 270 — 4 274 Cannasoul Collaboration Loan 26 — — 26 $ 2,563 $ 416 $ 41 $ 3,020 (i) During the three months ended March 31, 2022 and 2021, $nil and $416, respectively, were recorded to general and administrative expenses on the condensed consolidated statements of net income (loss) and comprehensive income (loss) as a result of adjustments to our expected credit losses. (ii) As of March 31, 2022 and December 31, 2021, loans receivable, net for the Natuera Series A Loan was $nil.

Derivative Liabilities

Derivative Liabilities	3 Months Ended
	Mar. 31, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Liabilities	Derivative LiabilitiesAs of March 31, 2022, Altria Group Inc. (“Altria”) beneficially held 156,573,537 of the Company’s common shares, an approximate 42% ownership interest in the Company (calculated on a non-diluted basis) and one warrant of the Company (the “Altria Warrant”). As summarized in this note, if exercised in full on such date, the exercise of the Altria Warrant would have resulted in Altria holding a total ownership interest in the Company of approximately 52% (calculated on a non-diluted basis). Pursuant to the investor rights agreement between the Company and Altria (the “Investor Rights Agreement”), entered into in connection with the closing of Altria’s investment in the Company (the “Altria Investment”) pursuant to a subscription agreement dated December 7, 2018, the Company granted Altria certain rights, among others, summarized in this note. The summaries below are qualified entirely by the terms and conditions fully set out in the Investor Rights Agreement and the Altria Warrant, as applicable. a. The Altria Warrant entitles the holder, subject to certain qualifications and limitations, to subscribe for and purchase up to an additional 10% of the common shares of Cronos (83,399,995 common shares as of March 31, 2022) at a per share exercise price of C$19.00, which expires on March 8, 2023. b. The Company granted to Altria, subject to certain qualifications and limitations, upon the occurrence of certain issuances of common shares of the Company executed by the Company (including issuances pursuant to the research and development (“R&D”) partnership (the “Ginkgo Strategic Partnership”) with Ginkgo Bioworks Holdings, Inc. (“Ginkgo”)), the right to purchase up to such number of common shares of the Company in order to maintain their ownership percentage of issued and outstanding common shares of the Company immediately preceding any issuance of shares by the Company (“Pre-emptive Rights”), at the same price per common share of the Company at which the common shares are sold in the relevant issuance; provided that if the consideration paid in connection with any such issuance is non-cash, the price per common share of the Company that would have been received had such common shares been issued for cash consideration will be determined by an independent committee (acting reasonably and in good faith); provided further that the price per common share of the Company to be paid by Altria pursuant to its exercise of its Pre-emptive Rights related to the Ginkgo Strategic Partnership will be C$16.25 per common share. These rights may not be exercised if Altria’s ownership percentage of the issued and outstanding shares of the Company falls below 20%. c. In addition to (and without duplication of) the Pre-emptive Rights, the Company granted to Altria, subject to certain qualifications and limitations, the right to subscribe for common shares of the Company issuable in connection with the exercise, conversion or exchange of convertible securities of the Company issued prior to March 8, 2019 or thereafter (excluding any convertible securities of the Company owned by Altria or any of its subsidiaries), a share incentive plan of the Company, the exercise of any right granted by the Company pro rata to all shareholders of the Company to purchase additional common shares and/or securities of the Company, bona fide bank debt, equipment financing or non-equity interim financing transactions that contemplate an equity component or bona fide acquisitions (including acquisitions of assets or rights under a license or otherwise), mergers or similar business combination transactions or joint ventures involving the Company in order to maintain their ownership percentage of issued and outstanding common shares of the Company immediately preceding any such transactions (“Top-up Rights”). Reconciliation of the Company’s derivative liabilities activity are as follows: As of January 1, 2022 Revaluation gain Exercise of rights Foreign exchange effect As of March 31, 2022 (a) Altria Warrant $ 13,720 $ (10,011) $ — $ 136 $ 3,845 (b) Pre-emptive Rights 180 (115) — 2 67 (c) Top-up Rights 475 (293) — 5 187 $ 14,375 $ (10,419) $ — $ 143 $ 4,099 As of January 1, 2021 Revaluation loss Exercise of rights Foreign exchange effect As of March 31, 2021 (a) Altria Warrant $ 138,858 $ 92,964 $ — $ 2,834 $ 234,656 (b) Pre-emptive Rights 12,095 7,833 — 245 20,173 (c) Top-up Rights 12,457 16,077 (11,278) 215 17,471 $ 163,410 $ 116,874 $ (11,278) $ 3,294 $ 272,300 Fluctuations in the Company’s share price are a primary driver for the changes in the derivative valuations during each reporting period. As the share price decreases for each of the related derivative instruments, the liability of the instrument generally decreases. Share price is one of the significant observable inputs used in the fair value measurement of each of the Company’s derivative instruments. The fair values of the derivative liabilities were determined using the Black-Scholes pricing model using the following inputs: As of March 31, 2022 Altria Warrant Pre-emptive Rights Top-up Rights Share price at valuation date (per share in C$) $4.85 $4.85 $4.85 Subscription price (per share in C$) $19 $16.25 $16.25 Weighted-average risk-free interest rate (i) 1.84% 1.31% 1.38% Weighted-average expected life (in years) (ii) 0.94 0.50 0.75 Expected annualized volatility (iii) 71% 71% 71% Expected dividend yield —% —% —% As of December 31, 2021 Altria Warrant Pre-emptive Rights Top-up Rights Share price at valuation date (per share in C$) $4.98 $4.98 $4.98 Subscription price (per share in C$) $19.00 $16.25 $16.25 Weighted-average risk-free interest rate (i) 0.79% 0.39% 0.50% Weighted-average expected life (in years) (ii) 1.18 0.50 0.80 Expected annualized volatility (iii) 80% 80% 80% Expected dividend yield —% —% —% (i) The risk-free interest rate was based on Bank of Canada government treasury bills and bonds with a remaining term equal to the expected life of the derivative liabilities. As of March 31, 2022 and December 31, 2021, the risk-free interest rate uses a range of approximately 0.60% to 2.28% and 0.16% to 1.10%, respectively, for the Pre-emptive Rights and Top-up Rights. (ii) The expected life represents the period of time, in years, that the derivative liabilities are expected to be outstanding. The expected life of the Pre-emptive Rights and Top-up Rights is determined based on the expected term of the underlying options, warrants, and shares, to which the Pre-emptive Rights and Top-up Rights are linked. As of March 31, 2022 and December 31, 2021, the expected life uses a range of approximately 0.25 years to 3.50 years and 0.25 years to 3.75 years, respectively, for the Pre-emptive Rights and Top-up Rights. (iii) Volatility was based on an equally weighted blended historical and implied volatility level of the underlying equity securities of the Company. The following table quantifies each of the significant inputs described above and provides a sensitivity analysis of the impact on the reported values of the derivative liabilities. The sensitivity analysis for each significant input is performed by assuming a 10% decrease in the input while other significant inputs remain constant at management’s best estimate as of the respective dates. While a decrease in the inputs noted below would cause a decrease in the carrying amount of the derivative liability, there would also be an equal and opposite impact on net income (loss). 10% decrease as of March 31, 2022 Altria Warrant Pre-emptive Rights Top-up Rights Share price $ 1,445 $ 34 $ 53 Weighted-average expected life 1,114 65 60 Expected annualized volatility 1,930 41 67 10% decrease as of December 31, 2021 Altria Warrant Pre-emptive Rights Top-up Rights Share price $ 3,970 $ 80 $ 123 Weighted-average expected life 2,971 171 133 Expected annualized volatility 5,402 96 155 These inputs are classified as Level 3 on the fair value hierarchy and are subject to volatility and several factors outside the Company’s control, which could significantly affect the fair value of these derivative liabilities in future periods.

Restructuring

Restructuring	3 Months Ended
	Mar. 31, 2022
Restructuring and Related Activities [Abstract]
Restructuring	Restructuring In the first quarter of 2022, the Company initiated a strategic plan to realign the business around its brands, centralize functions and evaluate the Company’s supply chain (the “Realignment”). As part of the Realignment, on February 28, 2022, the Board approved plans to leverage the Company’s strategic partnerships to improve supply chain efficiencies and reduce manufacturing overhead by exiting its production facility in Stayner, Ontario, Canada (the “Stayner Facility”). The organizational and cost reduction initiatives being undertaken are intended to position the Company to drive profitable and sustainable growth over time. The Company expects to spend approximately $5,800 in connection with the Realignment and the planned exit of the Stayner Facility, of which $3,084 has been incurred as of March 31, 2022. Estimated charges related to the exit of the Stayner Facility include employee-related costs such as severance, relocation and other termination benefits, as well as contract termination and other related costs. The Company expects to incur approximately $2,700 in additional charges related to the planned exit of the Stayner Facility, primarily in the second half of 2022. In addition, the Company anticipates capital expenditures of approximately $2,500 to modernize information technology systems and build distribution capabilities. These anticipated charges and capital expenditures are subject to a number of assumptions, including product costs, the timing of certain events, market factors and others. As a result of these assumptions, actual results may differ materially. The Company incurred the following restructuring costs by reportable segment: Three months ended March 31, 2022 2021 Rest of World $ 2,031 $ — United States 1,053 — Total $ 3,084 $ — The following table summarizes the Company’s restructuring activity for the three months ended March 31, 2022: Accrual as of December 31, 2021 Year-to-date expense Payments Accrual as of March 31, 2022 Employee termination benefits $ — $ 2,503 $ (1,249) $ 1,254 Other restructuring costs — 581 (437) 144 Total $ — $ 3,084 $ (1,686) $ 1,398

Share-based Payments

Share-based Payments	3 Months Ended
	Mar. 31, 2022
Share-based Payment Arrangement [Abstract]
Share-based Payments	Share-based Compensation (a) Share-based award plans The Company has granted stock options, restricted share units (“RSUs”) and deferred share units (“DSUs”) to employees and non-employee directors under the Stock Option Plan dated May 26, 2015 (the “2015 Stock Option Plan”), the 2018 Stock Option Plan dated June 28, 2018 (the “2018 Stock Option Plan” and, together with the 2015 Stock Option Plan, the “Prior Option Plans”), the Employment Inducement Award Plan #1 (the “Employment Inducement Award Plan”), the 2020 Omnibus Equity Incentive Plan dated March 29, 2020 (the “2020 Omnibus Plan”) and the DSU Plan dated August 10, 2019 (the “DSU Plan”). The Company can no longer make grants under the Prior Option Plans or the Employment Inducement Award Plan. The following table summarizes the total share-based compensation expense associated with the Company’s stock options and RSUs: Three months ended March 31, 2022 2021 Stock options $ 1,729 $ 2,064 RSUs 1,957 435 Total share-based compensation $ 3,686 $ 2,499 During the three months ended March 31, 2022, the Company recognized $1,583 of share-based compensation expense related to the severance of certain executives. (b) Stock options Vesting conditions for grants of options are determined by the Compensation Committee of the Company’s Board of Directors. The typical vesting for stock option grants made under the 2020 Omnibus Plan is annual vesting over three three five The following is a summary of the changes in stock options: Weighted-average exercise price (C$) (i) Number of options Weighted-average remaining contractual term (years) Balance as of January 1, 2022 $ 7.75 8,939,330 2.70 Exercise of options 3.14 (1,356,875) Cancellation, forfeiture and expiry of options 12.46 (55,791) Balance as of March 31, 2022 $ 8.55 7,526,664 1.72 Exercisable as of March 31, 2022 $ 7.96 4,654,574 1.14 Weighted-average exercise price (C$) (i) Number of options Weighted-average remaining contractual term (years) Balance as of January 1, 2021 $ 5.40 13,755,148 2.30 Exercise of options 2.13 (5,230,550) Cancellation, forfeiture and expiry of options 14.71 (25,771) Balance as of March 31, 2021 $ 7.38 8,498,827 2.82 Exercisable as of March 31, 2021 $ 5.75 4,896,820 1.46 (i) The weighted-average exercise price reflects the conversion of foreign currency-denominated stock options translated into C$ using the average foreign exchange rate as of the date of issuance. The following table summarizes stock options outstanding: As of March 31, 2022 As of December 31, 2021 2020 Omnibus Plan 2,900,000 2,900,000 2018 Stock Option Plan 1,523,449 1,550,074 2015 Stock Option Plan 3,103,215 4,489,256 Total stock options outstanding 7,526,664 8,939,330 (c) Restricted share units The following is a summary of the changes in RSUs: Weighted-average grant date fair value (C$) (i) Number of RSUs Balance as of January 1, 2022 $ 9.22 1,225,870 Granted (i) 3.52 3,950,334 Vested and issued 10.81 (78,631) Cancellation and forfeitures 7.92 (55,479) Balance as of March 31, 2022 $ 4.74 5,042,094 Weighted-average grant date fair value (C$) (ii) Number of RSUs Balance as of January 1, 2021 $ 7.66 948,357 Granted (i) 13.27 265,904 Balance as of March 31, 2021 $ 8.89 1,214,261 (i) RSUs granted in the period vest annually in equal installments over a three-year period from the grant date or vest after a three (ii) The weighted-average grant date fair value reflects the conversion of foreign currency-denominated RSUs translated into C$ using the foreign exchange rate as of the date of issuance. (d) Deferred share units The following is a summary of the changes in DSUs: Financial liability Number of DSUs Balance as of January 1, 2022 $ 408 104,442 Gain on revaluation (66) — Balance as of March 31, 2022 $ 342 104,442 Financial liability Number of DSUs Balance as of January 1, 2021 $ 577 83,293 Loss on revaluation 211 — Balance as of March 31, 2021 $ 788 83,293 (e) Warrants The following is a summary of the changes in warrants: Weighted-average exercise price (C$) Number of warrants Balance as of January 1, 2021 $ 0.25 7,987,349 Exercise of warrants 0.25 (7,977,349) Balance as of March 31, 2021 $ 0.25 10,000 As of March 31, 2022, there are no warrants outstanding other than the Altria Warrant. See Note 5 “ Derivative Liabilities ” for further description of the Altria Warrant.

Earnings (Loss) Per Share

Earnings (Loss) Per Share	3 Months Ended
	Mar. 31, 2022
Earnings Per Share [Abstract]
Earnings (Loss) Per Share	Earnings (Loss) per Share Basic and diluted earnings (loss) per share from continuing and discontinued operations are calculated as follows (in thousands, except share and per share amounts): Three months ended March 31, 2022 2021 Basic and diluted loss per share computation Net loss from continuing operations attributable to the shareholders of Cronos Group $ (32,638) $ (161,291) Weighted-average number of common shares outstanding for computation for basic and diluted earnings per share (i) 375,022,724 363,012,740 Basic loss from continuing operations per share $ (0.09) $ (0.44) Diluted loss from continuing operations per share $ (0.09) $ (0.44) Loss from discontinued operations attributable to the shareholders of Cronos Group $ — $ (21) Weighted-average number of common shares outstanding from computation for basic and diluted earnings per share 375,022,724 363,012,740 Basic loss from discontinued operations per share $ 0.00 $ 0.00 Diluted loss from discontinued operations per share $ 0.00 $ 0.00 (i) In computing diluted earnings per share, incremental common shares are not considered in periods in which a net loss is reported as the inclusion of the common share equivalents would be anti-dilutive. Total securities of 118,224,080 and 136,945,023 were not included in the computation of diluted shares outstanding for the three months ended March 31, 2022 and, 2021, respectively, because the effect would be anti-dilutive.

Segment Information

Segment Information	3 Months Ended
	Mar. 31, 2022
Segment Reporting [Abstract]
Segment Information	Segment Information The tables below set forth our condensed consolidated results of operations by segment. The Company’s condensed consolidated financial results for these periods are not necessarily indicative of the consolidated financial results that the Company will achieve in future periods . Segment data was as follows for the three months ended March 31, 2022 and 2021: Three months ended March 31, 2022 United States Rest of World Corporate Total Cannabis flower $ — $ 18,625 $ — $ 18,625 Cannabis extracts 2,328 3,988 — 6,316 Other — 92 — 92 Net revenue $ 2,328 $ 22,705 $ — $ 25,033 Total assets $ 441,064 $ 283,182 $ 646,755 $ 1,371,001 Depreciation and amortization 96 1,197 — 1,293 Adjusted EBITDA (7,086) (3,425) (8,389) (18,900) Purchase of property, plant and equipment, net — 711 — 711 Three months ended March 31, 2021 United States Rest of World Corporate Total Cannabis flower $ — $ 9,434 $ — $ 9,434 Cannabis extracts 2,441 703 — 3,144 Other — 33 — 33 Net revenue $ 2,441 $ 10,170 $ — $ 12,611 Share of loss from equity accounted investees $ — $ 1,643 $ — $ 1,643 Total assets $ 252,449 $ 394,442 $ 1,234,391 $ 1,881,282 Depreciation and amortization 71 664 — 735 Loss from discontinued operations — 21 — 21 Adjusted EBITDA (9,510) (22,184) (4,880) (36,574) Purchase of property, plant and equipment, net 80 6,600 — 6,680 The following tables set forth a reconciliation of net income (loss) as determined in accordance with U.S. GAAP to Adjusted EBITDA for the periods indicated: Three months ended March 31, 2022 United States Rest of World Corporate Total Net income (loss) $ (22,216) $ 2,014 $ (12,451) $ (32,653) Interest income, net (29) (2,017) — (2,046) Income tax expense — 362 — 362 Impairment loss on long-lived assets (i) — 3,493 — 3,493 Gain on revaluation of derivative liabilities (ii) — (10,419) — (10,419) Gain on revaluation of financial instruments (iv) — (4,268) — (4,268) Impairment loss on other investment (v) 11,238 — — 11,238 Foreign currency transaction loss — 1,872 — 1,872 Other, net (vi) — (135) — (135) Restructuring costs (viii) 1,053 2,031 — 3,084 Share-based compensation (ix) 2,436 1,250 — 3,686 Financial statement review costs (x) — — 4,062 4,062 Depreciation and amortization 432 2,392 — 2,824 Adjusted EBITDA $ (7,086) $ (3,425) $ (8,389) $ (18,900) Three months ended March 31, 2021 United States Rest of World Corporate Total Net loss $ (12,092) $ (142,147) $ (7,386) $ (161,625) Interest income, net (3) (2,326) — (2,329) Share of loss from equity accounted investments — 1,643 — 1,643 Impairment loss on long-lived assets (i) 1,741 — — 1,741 Loss on revaluation of derivative liabilities (ii) — 116,874 — 116,874 Transaction costs (iii) — — 501 501 Loss on revaluation of financial instruments (iv) — 200 — 200 Other, net (vi) — 16 — 16 Loss from discontinued operations (vii) — 21 — 21 Share-based compensation (ix) 745 1,754 — 2,499 Financial statement review costs (x) — — 2,005 2,005 Depreciation and amortization 99 1,781 — 1,880 Adjusted EBITDA $ (9,510) $ (22,184) $ (4,880) $ (36,574) (i) For the three months ended March 31, 2022, impairment loss on long-lived assets related to the Company’s decision to seek a sublease for leased office space located in Toronto, Ontario, Canada. For the three months ended March 31, 2021, impairment loss on long-lived assets related to an impairment on leased premises in the U.S. segment. See Note 12 “ Impairment Loss on Long-lived Assets .” (ii) For the three months ended March 31, 2022 and 2021, (gain) loss on revaluation of derivative liabilities represents the fair value changes on the derivative liabilities. See Note 5 “ Derivative Liabilities .” (iii) For the three months ended March 31, 2021, transaction costs represent legal, financial and other advisory fees and expenses incurred in connection with various strategic investments. These costs are included in general and administrative expenses on the condensed consolidated statements of net income (loss) and comprehensive income (loss). (iv) For the three months ended March 31, 2022, gain on revaluation of financial instruments related primarily to the Company’s equity securities in Cronos Australia. For the three months ended March 31, 2021, loss on revaluation of financial instruments related primarily to revaluations of financial liabilities resulting from DSUs. (v) For the three months ended March 31, 2022, impairment loss on other investments related to the PharmaCann Option for the difference between its fair value and carrying amount. See Note 3 “ Investments. ” (vi) For the three months ended March 31, 2022 and 2021, other, net is primarily related to (gain) loss on reclassification of held-for-sale assets and (gain) loss on disposal of assets. (vii) For the three months ended March 31, 2021, loss from discontinued operations related to the discontinuance of Original B.C. Ltd. (“OGBC”). (viii) For the three months ended March 31, 2022, restructuring costs related to the employee-related severance costs and other restructuring costs associated with the Realignment and the exit of the Stayner Facility. See Note 6 “ Restructuring. ” (ix) For the three months ended March 31, 2022 and 2021, share-based compensation related to the vesting expenses of share-based compensation awarded to employees under the Company’s share-based award plans as described in Note 7 “ Share-based Compensation .” (x) For the three months ended March 31, 2022 and 2021, financial statement review costs include costs related to the restatements of the Company’s 2019 and second quarter 2021 interim financial statements, costs related to the Company’s responses to requests for information from various regulatory authorities relating to such restatement and legal costs defending shareholder class action complaints brought against the Company as a result of the 2019 restatement. Net revenue attributed to a geographic region based on the location of the customer were as follows: Three months ended March 31, 2022 2021 Canada $ 13,576 $ 7,582 Israel 9,128 2,518 United States 2,329 2,441 Other countries — 70 Net revenue $ 25,033 $ 12,611 Property, plant and equipment, net were physically located in the following geographic regions: As of March 31, 2022 As of December 31, 2021 Canada $ 47,717 $ 49,117 Israel 23,823 24,473 United States 288 480 Total $ 71,828 $ 74,070

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2022
Loss Contingency [Abstract]
Commitments and Contingencies	Commitments and Contingencies (a) Commitments There have been no material changes in the information regarding commitments as disclosed in the Company’s Annual Report. (b) Contingencies The Company is subject to various legal proceedings in the ordinary course of its business and in connection with its marketing, distribution and sale of its products. Many of these legal proceedings are in the early stages of litigation and seek damages that are unspecified or not quantified. Although the outcome of these matters cannot be predicted with certainty, the Company does not believe these legal proceedings, individually or in the aggregate, will have a material adverse effect on its financial condition but could be material to its results of operations for a quarterly period depending, in part, on its results for that quarter. (i) Class action complaints relating to restatement of 2019 interim financial statements On March 11 and 12, 2020, two alleged shareholders of the Company separately filed two putative class action complaints in the U.S. District Court for the Eastern District of New York against the Company and its Chief Executive Officer and now former Chief Financial Officer. The court has consolidated the cases, and the consolidated amended complaint alleges violations of Section 10(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder against all defendants, and Section 20(a) of the Exchange Act against the individual defendants. The consolidated amended complaint generally alleges that certain of the Company’s prior public statements about revenues and internal control were incorrect based on the Company’s disclosures relating to the Audit Committee of the Board of Directors’ (the “Board”) review of the appropriateness of revenue recognized in connection with certain bulk resin purchases and sales of products through the wholesale channel. The consolidated amended complaint does not quantify a damage request. Defendants moved to dismiss on February 8, 2021. On June 3, 2020, an alleged shareholder filed a Statement of Claim, as amended on August 12, 2020, in the Ontario Superior Court of Justice in Toronto, Ontario, Canada, seeking, among other things, an order certifying the action as a class action on behalf of a putative class of shareholders and damages of an unspecified amount. The Amended Statement of Claim names (i) the Company, (ii) its Chief Executive Officer, (iii) now former Chief Financial Officer, (iv) former Chief Financial Officer and Chief Commercial Officer, and (v) current and former members of the Board as defendants and alleges breaches of the Ontario Securities Act, oppression under the Ontario Business Corporations Act and common law misrepresentation. The Amended Statement of Claim generally alleges that certain of the Company’s prior public statements about revenues and internal control were misrepresentations based on the Company’s March 2, 2020 disclosure that the Audit Committee of the Board was conducting a review of the appropriateness of revenue recognized in connection with certain bulk resin purchases and sales of products through the wholesale channel, and the Company’s subsequent restatement. The Amended Statement of Claim does not quantify a damage request. On June 28, 2021, the Court dismissed motions brought by the plaintiff for leave to commence a claim for misrepresentation under the Ontario Securities Act and for certification of the action as a class action. The plaintiff has appealed the Court’s dismissal of the motions only with respect to the Company, the Chief Executive Officer, and the now former Chief Financial Officer; the remaining defendants were dismissed from the matter with prejudice, and the Company and all individual defendants agreed not to seek costs from plaintiff in connection with the dismissal of the motions. (ii) Regulatory reviews relating to restatements The Company has been responding to requests for information from various regulatory authorities relating to its previously disclosed restatement of its financial statements for the first three quarters of 2019 as well as the previously disclosed restatement of the second quarter of 2021 interim financial statements. The Company is responding to all such requests for information and cooperating with all regulatory authorities. The Company cannot predict the outcome of any such regulatory review or investigation and it is possible that additional investigations or one or more formal proceedings may be commenced against the Company and its current and former officers and directors in connection with these regulatory reviews and investigations. (iii) Litigation relating to marketing, distribution and sale of products On June 16, 2020, an alleged consumer filed a Statement of Claim on behalf of a class in the Court of Queen’s Bench of Alberta in Alberta, Canada, against the Company and other Canadian cannabis manufacturers and/or distributors. On December 4, 2020, a Third Amended Statement of Claim was filed, which added a second alleged consumer. The Third Amended Statement of Claim alleges claims related to the defendants’ advertised content of cannabinoids in cannabis products for medicinal use on or after June 16, 2010 and cannabis products for adult use on or after October 17, 2018. The Third Amended Statement of Claim seeks a total of C$500 million for breach of contract, compensatory damages, and unjust enrichment or such other amount as may be proven in trial and C$5 million in punitive damages against each defendant, including the Company. The Third Amended Statement of Claim also seeks interest and costs associated with the action. The Company has not responded to the Third Amended Statement of Claim. On January 31, 2022, upon consent of the Company and the plaintiffs, the court dismissed the case in its entirety as to the Company. A number of claims, including purported class actions, have been brought in the U.S. against companies engaged in the U.S. hemp business alleging, among other things, violations of state consumer protection, health and advertising laws. On April 8, 2020, a putative class action complaint was filed in the U.S. District Court for the Central District of California against Redwood Holding Group, LLC (“Redwood”), alleging violations of California’s Unfair Competition Law, False Advertising Law, Consumers Legal Remedies Act, and breaches of the California Commercial Code for breach of express warranties and implied warranty of merchantability with respect to Redwood’s marketing and sale of U.S. hemp products. The complaint did not quantify a damage request. On April 10, 2020, the class action complaint was dismissed for certain pleading deficiencies and the plaintiff was granted leave until April 24, 2020 to amend the complaint to establish federal subject matter jurisdiction. On April 28, 2020, the action was dismissed without prejudice for failure to prosecute and for failure to comply with a court order. As of the date of this Quarterly Report, the plaintiff has not refiled the complaint.

Financial Instruments

Financial Instruments	3 Months Ended
	Mar. 31, 2022
Risks and Uncertainties [Abstract]
Financial Instruments	Fair Value Measurements The Company complies with ASC 820 Fair Value Measurements for its financial assets and liabilities that are re-measured and reported at fair value at each reporting period, and non-financial assets and liabilities that are re-measured and reported at fair value at least annually. In general, fair values are determined by: • Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. • Level 2 inputs utilize data points that are observable such as quoted prices, interest rates and yield curves. • Level 3 inputs are unobservable data points for the asset or liability, and includes situations where there is little, if any, market activity for the asset or liability. The following tables present information about the Company’s assets and liabilities that are measured at fair value on a recurring basis: March 31, 2022 Level 1 Level 2 Level 3 Total Cash and cash equivalents $ 861,535 $ — $ — $ 861,535 Short-term investments 119,933 — — 119,933 Other investments (i) 12,607 — — 12,607 Derivative liabilities — — 4,099 4,099 December 31, 2021 Level 1 Level 2 Level 3 Total Cash and cash equivalents $ 886,973 $ — $ — $ 886,973 Short-term investments 117,684 — — 117,684 Other investments (i) 8,000 — — 8,000 Derivative liabilities — — 14,375 14,375 (i) As of March 31, 2022 and December 31, 2021, the Company’s influence on Cronos Australia is deemed non-significant and the investment is considered an equity security with a readily determinable fair value. See Note 3 “ Investments ” for additional information. There were no transfers between fair value categories during the periods presented.

Impairment Loss on Long-lived A

Impairment Loss on Long-lived Assets	3 Months Ended
	Mar. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Impairment Loss on Long-lived Assets	Impairment Loss on Long-lived Assets (a) Right-of-use assets and property, plant, and equipment, net During the three months ended March 31, 2022, the Company recognized an impairment charge of $1,986 related to the right-of-use lease asset associated with the Company’s corporate headquarters, encompassing approximately 29,000 square feet, in Toronto, Ontario, Canada, for which the Company determined it would seek a sublease. In addition, the Company recognized an impairment charge of $1,507 during the three months ended March 31, 2022 related to leasehold improvements and other office equipment that it plans to include in any potential sublease agreement. The determination to seek a sublease of the property and include leasehold improvements and other office equipment in any potential sublease agreement triggered the impairment charges. Both of the impairment charges are recognized as impairment loss on long-lived assets on the condensed consolidated statements of net income (loss) and comprehensive income (loss). During the three months ended March 31, 2021, the Company recognized an impairment charge of $1,039 related to leasehold improvements located within leased premises, encompassing approximately 6,000 square feet, in Los Angeles, California, which the Company determined it no longer had plans to use. The significant change in the extent and manner in which the leasehold improvements are being used and the expectation that, more likely than not, the leasehold improvements will be disposed of before the end of their useful life triggered an impairment. The right-of-use lease asset associated with the leasehold improvements was also written down as a result of the Company’s decision to no longer use the leased premise. The Company recognized an impairment charge on the de-recognition of the right-of use asset of $702 during the three months ended March 31, 2021. Both the impairment charges are recognized as impairment loss on long-lived assets on the condensed consolidated statements of net income (loss) and comprehensive income (loss).

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2022
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions (a) Altria On March 8, 2019, in connection with the Altria Investment, Altria, through certain of its wholly owned subsidiaries, purchased a 45% equity interest in the Company. As of March 31, 2022, Altria beneficially held an approximately 42% ownership interest in the Company (calculated on a non-diluted basis). The Company incurred the following expenses for consulting services from Altria Pinnacle LLC, a subsidiary of Altria (“Altria Pinnacle”): Three months ended March 31, 2022 2021 Altria Pinnacle - expense $ 28 $ 8 As of March 31, 2022 and December 31, 2021, the Company had payables outstanding to Altria Pinnacle of $13 and $nil, respectively. (b) Cronos GrowCo The Company holds a variable interest in Cronos GrowCo through its ownership of 50% of Cronos GrowCo’s common shares and senior secured debt in Cronos GrowCo. See Note 3 “ Investments ” for additional information. The Company made the following purchases of cannabis products from Cronos GrowCo: Three months ended March 31, 2022 2021 Cronos GrowCo - purchases $ 3,218 $ — There were $nil and $82 amounts payable to Cronos GrowCo as of March 31, 2022 and December 31, 2021, respectively. Additionally, on August 23, 2019, the Company, as lender, and Cronos GrowCo, as borrower, entered into the GrowCo Facility. See Note 4 “ Loans Receivable, net ” for additional information.

Background, Basis of Presenta_2

Background, Basis of Presentation and Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of presentation	Basis of presentation The interim condensed consolidated financial statements of Cronos Group are unaudited. They have been prepared in accordance with Generally Accepted Accounting Principles in the United States (“U.S. GAAP”) for interim financial information and with applicable rules and regulations of the U.S. Securities and Exchange Commission relating to interim financial statements. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2022 are not necessarily indicative of the results that may be expected for any other reporting period. These condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and related notes included in its Annual Report on Form 10-K for the year ended December 31, 2021 (the “Annual Report”). Certain prior year amounts have been reclassified to conform to the current year presentation of our condensed consolidated financial statements. These reclassifications had no effect on the reported results of operations and ending shareholders’ equity.
Sales concentration risk	Concentration of risk Credit risk is the risk of financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations. The Company is exposed to credit risk from its operating activities, primarily accounts receivable and other receivables, and its investing activities, including cash held with banks and financial institutions, short-term investments, loans receivable, and advances to joint ventures. The Company’s maximum exposure to this risk is equal to the carrying amount of these financial assets, which amounted to $1,098,413 and $1,118,684 as of March 31, 2022 and December 31, 2021, respectively. An impairment analysis is performed at each reporting date using a provision matrix to measure expected credit losses. The provision rates are based on the days past due for groupings of various customer segments with similar loss patterns. The calculation reflects the probability-weighted outcome, the time value of money and reasonable and supportable information that is available at the reporting date about past events, current conditions and forecasts of future economic conditions. Accounts receivable are written off when there is no reasonable expectation of recovery. Indicators that there is no reasonable expectation of recovery include, amongst others, the failure of a debtor to engage in a repayment plan and a failure to make contractual payments for a period of greater than 120 days past due. As of March 31, 2022 and December 31, 2021, the Company had $9 and $8, respectively, in expected credit losses that have been recognized on receivables from contracts with customers in the Rest of World (“ROW”) segment. As of March 31, 2022 and December 31, 2021, the Company had $138 and $104, respectively, in expected credit losses that have been recognized on receivables from contracts with customers in the United States (“U.S.”) segment.
Segment information	Segment information Segment reporting is prepared on the same basis that the Company’s chief operating decision makers (the “CODMs”) manage the business, make operating decisions and assess the Company’s performance. The Company determined that it has the following two reportable segments: U.S. (the “U.S. segment”) and ROW (the “ROW segment”). The U.S. operating segment consists of the manufacture and distribution of U.S. hemp-derived cannabinoid infused products. The ROW operating segment is involved in the cultivation, manufacture, and marketing of cannabis and cannabis-derived products for the medical and adult-use markets . These two segments represent the geographic regions in which the Company operates and the different product offerings within each geographic region. The results of each segment are regularly reviewed by the CODMs to assess the performance of the segment and make decisions regarding the allocation of resources using Adjusted EBITDA (as defined below) as the measure of segment profit or loss. Adjusted EBITDA is defined as earnings before interest, tax, depreciation, non-cash items and items that do not reflect management’s assessment of ongoing business performance.
Adoption of new accounting pronouncements and New accounting pronouncements not yet adopted	Adoption of new accounting pronouncements On January 1, 2022, the Company adopted ASU No. 2020-06, Debt –Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815–40) (“ASU No. 2020-06”). ASU No. 2020-06 simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. ASU No. 2020-06 is part of the FASB’s simplification initiative, which aims to reduce unnecessary complexity in U.S. GAAP. The adoption of ASU No. 2020-06 did not have an impact on the Company’s interim condensed consolidated financial statements. (f) New accounting pronouncements not yet adopted In March 2022, the FASB issued ASU 2022-02, Financial Instruments – Credit Losses (Topic 326) (“ASU No. 2022-02”). ASU No. 2022-02 eliminates the existing troubled debt restructuring recognition and measurement guidance, and instead aligns the accounting treatment to that of other loan modifications. The amendments enhance existing disclosure requirements and introduce new requirements related to certain modifications of receivables made to borrowers experiencing financial difficulty. ASU No. 2022-02 also requires that entities disclose current-period gross write-offs by year of origination for financing receivables and net investments in leases. ASU No. 2022-02 is effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years, and is to be adopted prospectively. The Company does not expect the adoption of ASU No. 2022-02 to have a material impact on its condensed consolidated financial statements.

Inventory, net (Tables)

Inventory, net (Tables)	3 Months Ended
	Mar. 31, 2022
Inventory Disclosure [Abstract]
Schedule of Inventory, net	Inventory, net is comprised of the following items: As of March 31, 2022 As of December 31, 2021 Raw materials $ 8,523 $ 9,211 Work-in-progress 12,353 12,405 Finished goods 15,587 10,778 Supplies and consumables 591 408 Total $ 37,054 $ 32,802

Investments (Tables)

Investments (Tables)	3 Months Ended
	Mar. 31, 2022
Equity Method Investments and Joint Ventures [Abstract]
Schedule of Investments in Associates and Joint Ventures	A reconciliation of the carrying amount of the investments in equity method investees, net is as follows: Ownership interest As of March 31, 2022 As of December 31, 2021 Cronos Growing Company Inc. (“Cronos GrowCo”) 50% $ 17,084 $ 16,764 NatuEra S.à.r.l. (“Natuera”) 50% — — $ 17,084 $ 16,764 The following is a summary of the Company’s share of net losses from equity investments accounted for under the equity method of accounting: For the three months ended March 31, 2022 2021 Cronos GrowCo $ — $ (299) Natuera — (1,344) $ — $ (1,643)
Summary of Gain on Revaluation of Other Investments	The following table summarizes the Company’s other investments activity: As of December 31, 2021 Unrealized gain Impairment charges Foreign exchange effect As of March 31, 2022 PharmaCann $ 110,392 $ — $ (11,238) $ — $ 99,154 Cronos Australia 8,000 4,196 — 411 12,607 $ 118,392 $ 4,196 $ (11,238) $ 411 $ 111,761

Loans Receivable, net (Tables)

Loans Receivable, net (Tables)	3 Months Ended
	Mar. 31, 2022
Receivables [Abstract]
Schedule of Loan Receivable	Loans receivable, net consists of the following: As of March 31, 2022 As of December 31, 2021 GrowCo Facility (i) $ 3,198 $ 3,138 Add: Current portion of accrued interest 3,037 2,322 Total current portion of loans receivable 6,235 5,460 GrowCo Facility (i) 64,801 64,367 Mucci Promissory Note 14,414 14,019 Cannasoul Collaboration Loan (ii) 2,192 2,249 Add: Long-term portion of accrued interest 122 — Total long-term portion of loans receivable 81,529 80,635 Total loans receivable, net $ 87,764 $ 86,095 (i) On August 23, 2019, the Company, as lender, and Cronos GrowCo, as borrower, entered into a senior secured credit agreement for an aggregate principal amount of C$100,000 (the “GrowCo Facility”). In August 2021, the GrowCo Facility was amended to increase the aggregate principal amount available to C$105,000. As of March 31, 2022 and December 31, 2021, Cronos GrowCo had outstanding borrowings of C$103,000 ($82,354) and C$104,000 ($81,598), respectively, from the GrowCo Facility. As of March 31, 2022, Cronos GrowCo had repaid C$1,000 ($800) under the terms of the GrowCo Facility. The available borrowing capacity under the GrowCo Facility was C$1,000 ($800) at March 31, 2022 and December 31, 2021. (ii) As of March 31, 2022 and December 31, 2021, CLS has received ILS 8,297 ($2,600) and ILS 8,297 ($2,664), respectively, from the Cannasoul Collaboration Loan.
Schedule of Expected Credit Loss Allowances	Expected credit loss allowances on the Company’s long-term financial assets was comprised of the following items: As of January 1, 2022 Increase (decrease) (i) Foreign exchange effect As of March 31, 2022 GrowCo Facility $ 14,089 $ (4) $ 269 $ 14,354 Mucci Promissory Note 90 1 2 93 Cannasoul Collaboration Loan 415 3 (9) 409 $ 14,594 $ — $ 262 $ 14,856 As of January 1, 2021 Increase (decrease) (i) Foreign exchange effect As of March 31, 2021 GrowCo Facility $ 1,546 $ — $ 23 $ 1,569 Natuera Series A Loan (ii) 721 416 14 1,151 Mucci Promissory Note 270 — 4 274 Cannasoul Collaboration Loan 26 — — 26 $ 2,563 $ 416 $ 41 $ 3,020 (i) During the three months ended March 31, 2022 and 2021, $nil and $416, respectively, were recorded to general and administrative expenses on the condensed consolidated statements of net income (loss) and comprehensive income (loss) as a result of adjustments to our expected credit losses. (ii) As of March 31, 2022 and December 31, 2021, loans receivable, net for the Natuera Series A Loan was $nil.

Derivative Liabilities (Tables)

Derivative Liabilities (Tables)	3 Months Ended
	Mar. 31, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Reconciliation of Carrying Amounts	Reconciliation of the Company’s derivative liabilities activity are as follows: As of January 1, 2022 Revaluation gain Exercise of rights Foreign exchange effect As of March 31, 2022 (a) Altria Warrant $ 13,720 $ (10,011) $ — $ 136 $ 3,845 (b) Pre-emptive Rights 180 (115) — 2 67 (c) Top-up Rights 475 (293) — 5 187 $ 14,375 $ (10,419) $ — $ 143 $ 4,099 As of January 1, 2021 Revaluation loss Exercise of rights Foreign exchange effect As of March 31, 2021 (a) Altria Warrant $ 138,858 $ 92,964 $ — $ 2,834 $ 234,656 (b) Pre-emptive Rights 12,095 7,833 — 245 20,173 (c) Top-up Rights 12,457 16,077 (11,278) 215 17,471 $ 163,410 $ 116,874 $ (11,278) $ 3,294 $ 272,300
Schedule of Fair Values of Derivative Liabilities	The fair values of the derivative liabilities were determined using the Black-Scholes pricing model using the following inputs: As of March 31, 2022 Altria Warrant Pre-emptive Rights Top-up Rights Share price at valuation date (per share in C$) $4.85 $4.85 $4.85 Subscription price (per share in C$) $19 $16.25 $16.25 Weighted-average risk-free interest rate (i) 1.84% 1.31% 1.38% Weighted-average expected life (in years) (ii) 0.94 0.50 0.75 Expected annualized volatility (iii) 71% 71% 71% Expected dividend yield —% —% —% As of December 31, 2021 Altria Warrant Pre-emptive Rights Top-up Rights Share price at valuation date (per share in C$) $4.98 $4.98 $4.98 Subscription price (per share in C$) $19.00 $16.25 $16.25 Weighted-average risk-free interest rate (i) 0.79% 0.39% 0.50% Weighted-average expected life (in years) (ii) 1.18 0.50 0.80 Expected annualized volatility (iii) 80% 80% 80% Expected dividend yield —% —% —% (i) The risk-free interest rate was based on Bank of Canada government treasury bills and bonds with a remaining term equal to the expected life of the derivative liabilities. As of March 31, 2022 and December 31, 2021, the risk-free interest rate uses a range of approximately 0.60% to 2.28% and 0.16% to 1.10%, respectively, for the Pre-emptive Rights and Top-up Rights. (ii) The expected life represents the period of time, in years, that the derivative liabilities are expected to be outstanding. The expected life of the Pre-emptive Rights and Top-up Rights is determined based on the expected term of the underlying options, warrants, and shares, to which the Pre-emptive Rights and Top-up Rights are linked. As of March 31, 2022 and December 31, 2021, the expected life uses a range of approximately 0.25 years to 3.50 years and 0.25 years to 3.75 years, respectively, for the Pre-emptive Rights and Top-up Rights. (iii) Volatility was based on an equally weighted blended historical and implied volatility level of the underlying equity securities of the Company.
Schedule of Sensitivity Analysis	The following table quantifies each of the significant inputs described above and provides a sensitivity analysis of the impact on the reported values of the derivative liabilities. The sensitivity analysis for each significant input is performed by assuming a 10% decrease in the input while other significant inputs remain constant at management’s best estimate as of the respective dates. While a decrease in the inputs noted below would cause a decrease in the carrying amount of the derivative liability, there would also be an equal and opposite impact on net income (loss). 10% decrease as of March 31, 2022 Altria Warrant Pre-emptive Rights Top-up Rights Share price $ 1,445 $ 34 $ 53 Weighted-average expected life 1,114 65 60 Expected annualized volatility 1,930 41 67 10% decrease as of December 31, 2021 Altria Warrant Pre-emptive Rights Top-up Rights Share price $ 3,970 $ 80 $ 123 Weighted-average expected life 2,971 171 133 Expected annualized volatility 5,402 96 155

Restructuring (Tables)

Restructuring (Tables)	3 Months Ended
	Mar. 31, 2022
Restructuring and Related Activities [Abstract]
Schedule of Plan Information and Restructuring-Related Costs	The Company incurred the following restructuring costs by reportable segment: Three months ended March 31, 2022 2021 Rest of World $ 2,031 $ — United States 1,053 — Total $ 3,084 $ — The following table summarizes the Company’s restructuring activity for the three months ended March 31, 2022: Accrual as of December 31, 2021 Year-to-date expense Payments Accrual as of March 31, 2022 Employee termination benefits $ — $ 2,503 $ (1,249) $ 1,254 Other restructuring costs — 581 (437) 144 Total $ — $ 3,084 $ (1,686) $ 1,398

Share-based Payments (Tables)

Share-based Payments (Tables)	3 Months Ended
	Mar. 31, 2022
Share-based Payment Arrangement [Abstract]
Summary of Stock-based Compensation Expense	The following table summarizes the total share-based compensation expense associated with the Company’s stock options and RSUs: Three months ended March 31, 2022 2021 Stock options $ 1,729 $ 2,064 RSUs 1,957 435 Total share-based compensation $ 3,686 $ 2,499 During the three months ended March 31, 2022, the Company recognized $1,583 of share-based compensation expense related to the severance of certain executives.
Summary of the Changes in Options and Options Outstanding	The following is a summary of the changes in stock options: Weighted-average exercise price (C$) (i) Number of options Weighted-average remaining contractual term (years) Balance as of January 1, 2022 $ 7.75 8,939,330 2.70 Exercise of options 3.14 (1,356,875) Cancellation, forfeiture and expiry of options 12.46 (55,791) Balance as of March 31, 2022 $ 8.55 7,526,664 1.72 Exercisable as of March 31, 2022 $ 7.96 4,654,574 1.14 Weighted-average exercise price (C$) (i) Number of options Weighted-average remaining contractual term (years) Balance as of January 1, 2021 $ 5.40 13,755,148 2.30 Exercise of options 2.13 (5,230,550) Cancellation, forfeiture and expiry of options 14.71 (25,771) Balance as of March 31, 2021 $ 7.38 8,498,827 2.82 Exercisable as of March 31, 2021 $ 5.75 4,896,820 1.46 (i) The weighted-average exercise price reflects the conversion of foreign currency-denominated stock options translated into C$ using the average foreign exchange rate as of the date of issuance. The following table summarizes stock options outstanding: As of March 31, 2022 As of December 31, 2021 2020 Omnibus Plan 2,900,000 2,900,000 2018 Stock Option Plan 1,523,449 1,550,074 2015 Stock Option Plan 3,103,215 4,489,256 Total stock options outstanding 7,526,664 8,939,330
Summary of Changes in RSUs	The following is a summary of the changes in RSUs: Weighted-average grant date fair value (C$) (i) Number of RSUs Balance as of January 1, 2022 $ 9.22 1,225,870 Granted (i) 3.52 3,950,334 Vested and issued 10.81 (78,631) Cancellation and forfeitures 7.92 (55,479) Balance as of March 31, 2022 $ 4.74 5,042,094 Weighted-average grant date fair value (C$) (ii) Number of RSUs Balance as of January 1, 2021 $ 7.66 948,357 Granted (i) 13.27 265,904 Balance as of March 31, 2021 $ 8.89 1,214,261 (i) RSUs granted in the period vest annually in equal installments over a three-year period from the grant date or vest after a three
Summary of Changes in DSUs and Warrants	The following is a summary of the changes in DSUs: Financial liability Number of DSUs Balance as of January 1, 2022 $ 408 104,442 Gain on revaluation (66) — Balance as of March 31, 2022 $ 342 104,442 Financial liability Number of DSUs Balance as of January 1, 2021 $ 577 83,293 Loss on revaluation 211 — Balance as of March 31, 2021 $ 788 83,293 (e) Warrants The following is a summary of the changes in warrants: Weighted-average exercise price (C$) Number of warrants Balance as of January 1, 2021 $ 0.25 7,987,349 Exercise of warrants 0.25 (7,977,349) Balance as of March 31, 2021 $ 0.25 10,000

Earnings (Loss) Per Share (Tabl

Earnings (Loss) Per Share (Tables)	3 Months Ended
	Mar. 31, 2022
Earnings Per Share [Abstract]
Schedule of Earnings (Loss) Per Share	Basic and diluted earnings (loss) per share from continuing and discontinued operations are calculated as follows (in thousands, except share and per share amounts): Three months ended March 31, 2022 2021 Basic and diluted loss per share computation Net loss from continuing operations attributable to the shareholders of Cronos Group $ (32,638) $ (161,291) Weighted-average number of common shares outstanding for computation for basic and diluted earnings per share (i) 375,022,724 363,012,740 Basic loss from continuing operations per share $ (0.09) $ (0.44) Diluted loss from continuing operations per share $ (0.09) $ (0.44) Loss from discontinued operations attributable to the shareholders of Cronos Group $ — $ (21) Weighted-average number of common shares outstanding from computation for basic and diluted earnings per share 375,022,724 363,012,740 Basic loss from discontinued operations per share $ 0.00 $ 0.00 Diluted loss from discontinued operations per share $ 0.00 $ 0.00 (i) In computing diluted earnings per share, incremental common shares are not considered in periods in which a net loss is reported as the inclusion of the common share equivalents would be anti-dilutive.

Segment Information (Tables)

Segment Information (Tables)	3 Months Ended
	Mar. 31, 2022
Segment Reporting [Abstract]
Schedule of Segment Data and Adjusted EBITDA	Segment data was as follows for the three months ended March 31, 2022 and 2021: Three months ended March 31, 2022 United States Rest of World Corporate Total Cannabis flower $ — $ 18,625 $ — $ 18,625 Cannabis extracts 2,328 3,988 — 6,316 Other — 92 — 92 Net revenue $ 2,328 $ 22,705 $ — $ 25,033 Total assets $ 441,064 $ 283,182 $ 646,755 $ 1,371,001 Depreciation and amortization 96 1,197 — 1,293 Adjusted EBITDA (7,086) (3,425) (8,389) (18,900) Purchase of property, plant and equipment, net — 711 — 711 Three months ended March 31, 2021 United States Rest of World Corporate Total Cannabis flower $ — $ 9,434 $ — $ 9,434 Cannabis extracts 2,441 703 — 3,144 Other — 33 — 33 Net revenue $ 2,441 $ 10,170 $ — $ 12,611 Share of loss from equity accounted investees $ — $ 1,643 $ — $ 1,643 Total assets $ 252,449 $ 394,442 $ 1,234,391 $ 1,881,282 Depreciation and amortization 71 664 — 735 Loss from discontinued operations — 21 — 21 Adjusted EBITDA (9,510) (22,184) (4,880) (36,574) Purchase of property, plant and equipment, net 80 6,600 — 6,680 The following tables set forth a reconciliation of net income (loss) as determined in accordance with U.S. GAAP to Adjusted EBITDA for the periods indicated: Three months ended March 31, 2022 United States Rest of World Corporate Total Net income (loss) $ (22,216) $ 2,014 $ (12,451) $ (32,653) Interest income, net (29) (2,017) — (2,046) Income tax expense — 362 — 362 Impairment loss on long-lived assets (i) — 3,493 — 3,493 Gain on revaluation of derivative liabilities (ii) — (10,419) — (10,419) Gain on revaluation of financial instruments (iv) — (4,268) — (4,268) Impairment loss on other investment (v) 11,238 — — 11,238 Foreign currency transaction loss — 1,872 — 1,872 Other, net (vi) — (135) — (135) Restructuring costs (viii) 1,053 2,031 — 3,084 Share-based compensation (ix) 2,436 1,250 — 3,686 Financial statement review costs (x) — — 4,062 4,062 Depreciation and amortization 432 2,392 — 2,824 Adjusted EBITDA $ (7,086) $ (3,425) $ (8,389) $ (18,900) Three months ended March 31, 2021 United States Rest of World Corporate Total Net loss $ (12,092) $ (142,147) $ (7,386) $ (161,625) Interest income, net (3) (2,326) — (2,329) Share of loss from equity accounted investments — 1,643 — 1,643 Impairment loss on long-lived assets (i) 1,741 — — 1,741 Loss on revaluation of derivative liabilities (ii) — 116,874 — 116,874 Transaction costs (iii) — — 501 501 Loss on revaluation of financial instruments (iv) — 200 — 200 Other, net (vi) — 16 — 16 Loss from discontinued operations (vii) — 21 — 21 Share-based compensation (ix) 745 1,754 — 2,499 Financial statement review costs (x) — — 2,005 2,005 Depreciation and amortization 99 1,781 — 1,880 Adjusted EBITDA $ (9,510) $ (22,184) $ (4,880) $ (36,574) (i) For the three months ended March 31, 2022, impairment loss on long-lived assets related to the Company’s decision to seek a sublease for leased office space located in Toronto, Ontario, Canada. For the three months ended March 31, 2021, impairment loss on long-lived assets related to an impairment on leased premises in the U.S. segment. See Note 12 “ Impairment Loss on Long-lived Assets .” (ii) For the three months ended March 31, 2022 and 2021, (gain) loss on revaluation of derivative liabilities represents the fair value changes on the derivative liabilities. See Note 5 “ Derivative Liabilities .” (iii) For the three months ended March 31, 2021, transaction costs represent legal, financial and other advisory fees and expenses incurred in connection with various strategic investments. These costs are included in general and administrative expenses on the condensed consolidated statements of net income (loss) and comprehensive income (loss). (iv) For the three months ended March 31, 2022, gain on revaluation of financial instruments related primarily to the Company’s equity securities in Cronos Australia. For the three months ended March 31, 2021, loss on revaluation of financial instruments related primarily to revaluations of financial liabilities resulting from DSUs. (v) For the three months ended March 31, 2022, impairment loss on other investments related to the PharmaCann Option for the difference between its fair value and carrying amount. See Note 3 “ Investments. ” (vi) For the three months ended March 31, 2022 and 2021, other, net is primarily related to (gain) loss on reclassification of held-for-sale assets and (gain) loss on disposal of assets. (vii) For the three months ended March 31, 2021, loss from discontinued operations related to the discontinuance of Original B.C. Ltd. (“OGBC”). (viii) For the three months ended March 31, 2022, restructuring costs related to the employee-related severance costs and other restructuring costs associated with the Realignment and the exit of the Stayner Facility. See Note 6 “ Restructuring. ” (ix) For the three months ended March 31, 2022 and 2021, share-based compensation related to the vesting expenses of share-based compensation awarded to employees under the Company’s share-based award plans as described in Note 7 “ Share-based Compensation .” (x) For the three months ended March 31, 2022 and 2021, financial statement review costs include costs related to the restatements of the Company’s 2019 and second quarter 2021 interim financial statements, costs related to the Company’s responses to requests for information from various regulatory authorities relating to such restatement and legal costs defending shareholder class action complaints brought against the Company as a result of the 2019 restatement.
Schedule of Revenue from External Customers by Geographic Areas	Net revenue attributed to a geographic region based on the location of the customer were as follows: Three months ended March 31, 2022 2021 Canada $ 13,576 $ 7,582 Israel 9,128 2,518 United States 2,329 2,441 Other countries — 70 Net revenue $ 25,033 $ 12,611
Schedule of Long-lived Assets by Geographic Areas	Property, plant and equipment, net were physically located in the following geographic regions: As of March 31, 2022 As of December 31, 2021 Canada $ 47,717 $ 49,117 Israel 23,823 24,473 United States 288 480 Total $ 71,828 $ 74,070

Financial Instruments (Tables)

Financial Instruments (Tables)	3 Months Ended
	Mar. 31, 2022
Risks and Uncertainties [Abstract]
Schedule of Fair Value of Assets Measured on Recurring Basis	The following tables present information about the Company’s assets and liabilities that are measured at fair value on a recurring basis: March 31, 2022 Level 1 Level 2 Level 3 Total Cash and cash equivalents $ 861,535 $ — $ — $ 861,535 Short-term investments 119,933 — — 119,933 Other investments (i) 12,607 — — 12,607 Derivative liabilities — — 4,099 4,099 December 31, 2021 Level 1 Level 2 Level 3 Total Cash and cash equivalents $ 886,973 $ — $ — $ 886,973 Short-term investments 117,684 — — 117,684 Other investments (i) 8,000 — — 8,000 Derivative liabilities — — 14,375 14,375 (i) As of March 31, 2022 and December 31, 2021, the Company’s influence on Cronos Australia is deemed non-significant and the investment is considered an equity security with a readily determinable fair value. See Note 3 “ Investments ” for additional information.

Related Party Transactions (Tab

Related Party Transactions (Tables)	3 Months Ended
	Mar. 31, 2022
Related Party Transactions [Abstract]
Schedule of Related Party Transactions	The Company incurred the following expenses for consulting services from Altria Pinnacle LLC, a subsidiary of Altria (“Altria Pinnacle”): Three months ended March 31, 2022 2021 Altria Pinnacle - expense $ 28 $ 8 The Company made the following purchases of cannabis products from Cronos GrowCo: Three months ended March 31, 2022 2021 Cronos GrowCo - purchases $ 3,218 $ —

Background, Basis of Presenta_3

Background, Basis of Presentation and Accounting Policies (Details) $ in Thousands	3 Months Ended		6 Months Ended
	Mar. 31, 2022USD ($)segment	Mar. 31, 2021USD ($)	Jun. 30, 2021USD ($)	Dec. 31, 2021USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of reportable segments | segment	2
Concentration Risk [Line Items]
Maximum exposure to credit risk	$ 1,098,413		$ 1,118,684
Net revenue, before excise taxes	29,406	$ 14,654
Rest of World
Concentration Risk [Line Items]
Current expected credit loss allowance on accounts receivable	9			$ 8
United States
Concentration Risk [Line Items]
Current expected credit loss allowance on accounts receivable	$ 138			$ 104
Three Customers | Accounts Receivable | Credit Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage	72.00%
Four Customers | Accounts Receivable | Credit Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage			88.00%
Two Major Customers | Rest of World
Concentration Risk [Line Items]
Net revenue, before excise taxes	$ 9,833
Two Major Customers | Rest of World | Revenue Benchmark | Customer Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage	33.00%
Four Major Customers | Rest of World | Revenue Benchmark | Customer Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage		61.00%
Net revenue, before excise taxes		$ 8,963

Inventory, net (Details)

Inventory, net (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Inventory Disclosure [Abstract]
Raw materials	$ 8,523	$ 9,211
Work-in-progress	12,353	12,405
Finished goods	15,587	10,778
Supplies and consumables	591	408
Inventory, net	$ 37,054	$ 32,802

Investments - Schedule of Inves

Investments - Schedule of Investments in Associates and Joint Ventures (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Schedule of Equity Method Investments [Line Items]
Investments in equity accounted investees, net	$ 17,084		$ 16,764
Share of loss from investments in equity accounted investees	$ 0	$ (1,643)
Cronos GrowCo
Schedule of Equity Method Investments [Line Items]
Ownership interest	50.00%
Investments in equity accounted investees, net	$ 17,084		16,764
Share of loss from investments in equity accounted investees	$ 0	(299)
Natuera
Schedule of Equity Method Investments [Line Items]
Ownership interest	50.00%
Investments in equity accounted investees, net	$ 0		$ 0
Share of loss from investments in equity accounted investees	$ 0	$ (1,344)

Investments - Narrative (Detail

Investments - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Feb. 28, 2022
Variable Interest Entity [Line Items]
Impairment loss on other investments	$ 11,238	$ 0
PharmaCann
Variable Interest Entity [Line Items]
Impairment loss on other investments	$ 11,238
PharmaCann
Variable Interest Entity [Line Items]
Ownership interest			10.50%	6.40%
Cronos Australia
Variable Interest Entity [Line Items]
Ownership interest	10.00%
PharmaCann
Variable Interest Entity [Line Items]
Sale of stock, number of shares issued in transaction (in shares)			473,787

Investments - Revaluation of Ot

Investments - Revaluation of Other Investments (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Other Investments [Roll Forward]
Other investments, beginning balance	$ 118,392
Unrealized gain	4,196
Impairment charges	(11,238)	$ 0
Foreign exchange effect	411
Other investments, ending balance	111,761
PharmaCann
Other Investments [Roll Forward]
Other investments, beginning balance	110,392
Unrealized gain	0
Impairment charges	(11,238)
Foreign exchange effect	0
Other investments, ending balance	99,154
Cronos Australia
Other Investments [Roll Forward]
Other investments, beginning balance	8,000
Unrealized gain	4,196
Impairment charges	0
Foreign exchange effect	411
Other investments, ending balance	$ 12,607

Loans Receivable, net - Schedul

Loans Receivable, net - Schedule of Loan Receivable (Details) ₪ in Thousands, $ in Thousands	3 Months Ended			12 Months Ended
	Mar. 31, 2022USD ($)	Mar. 31, 2022CAD ($)	Mar. 31, 2021USD ($)	Dec. 31, 2021USD ($)	Dec. 31, 2021CAD ($)	Mar. 31, 2022CAD ($)	Mar. 31, 2022ILS (₪)	Dec. 31, 2021CAD ($)	Dec. 31, 2021ILS (₪)	Aug. 31, 2021CAD ($)	Aug. 31, 2019CAD ($)
Accounts, Notes, Loans and Financing Receivable [Line Items]
Total current portion of loans receivable	$ 6,235			$ 5,460
Total long-term portion of loans receivable	81,529			80,635
Total loans receivable, net	87,764			86,095
Draw downs	0		$ 2,645
Proceeds from repayment of loans receivable	790		$ 0
Loans Receivable
Accounts, Notes, Loans and Financing Receivable [Line Items]
Add: Current portion of accrued interest	3,037			2,322
Add: Long-term portion of accrued interest	122			0
GrowCo Facility | Loans Receivable
Accounts, Notes, Loans and Financing Receivable [Line Items]
Current portion of loans receivable, before accrued interest	3,198			3,138
Long term portion of loans receivable, before accrued interest	64,801			64,367
Face amount										$ 105,000,000	$ 100,000,000
Draw downs	82,354	$ 103,000,000		81,598	$ 104,000,000
Proceeds from repayment of loans receivable	800	$ 1,000,000
Available borrowing capacity						$ 1,000,000		$ 800,000
Mucci Promissory Note | Loans Receivable
Accounts, Notes, Loans and Financing Receivable [Line Items]
Long term portion of loans receivable, before accrued interest	14,414			14,019
Cannasoul Collaboration Loan | Loans Receivable
Accounts, Notes, Loans and Financing Receivable [Line Items]
Long term portion of loans receivable, before accrued interest	2,192			2,249
Cannasoul Collaboration Loan | Loans Receivable | Establishment of a Commercial Cannabis Analytical Testing Laboratory | Cannasoul | Variable Interest Entity, Not Primary Beneficiary
Accounts, Notes, Loans and Financing Receivable [Line Items]
Collaborative arrangement, installment received	$ 2,600			$ 2,664			₪ 8,297		₪ 8,297

Loans Receivable, net - Sched_2

Loans Receivable, net - Schedule of Expected Credit Loss Allowances (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Allowance for Loan and Lease Losses [Roll Forward]
Beginning balance	$ 14,594,000	$ 2,563,000
Increase (decrease)	0	416,000
Foreign exchange effect	262,000	41,000
Ending balance	14,856,000	3,020,000
Financing receivable, credit loss, expense, including transferred into investment	0	416,000
GrowCo Facility | Loans Receivable
Allowance for Loan and Lease Losses [Roll Forward]
Beginning balance	14,089,000	1,546,000
Increase (decrease)	(4,000)	0
Foreign exchange effect	269,000	23,000
Ending balance	14,354,000	1,569,000
Mucci Promissory Note | Loans Receivable
Allowance for Loan and Lease Losses [Roll Forward]
Beginning balance	90,000	270,000
Increase (decrease)	1,000	0
Foreign exchange effect	2,000	4,000
Ending balance	93,000	274,000
Cannasoul Collaboration Loan | Loans Receivable
Allowance for Loan and Lease Losses [Roll Forward]
Beginning balance	415,000	26,000
Increase (decrease)	3,000	0
Foreign exchange effect	(9,000)	0
Ending balance	409,000	26,000
Natuera Series A Loan(ii) | Loans Receivable
Allowance for Loan and Lease Losses [Roll Forward]
Beginning balance	0	721,000
Increase (decrease)		416,000
Foreign exchange effect		14,000
Ending balance	$ 0	$ 1,151,000

Derivative Liabilities - Narrat

Derivative Liabilities - Narrative (Details)	3 Months Ended
	Mar. 31, 2022warrant$ / sharesshares	Dec. 31, 2021shares	Mar. 08, 2019
Derivative [Line Items]
Common stock, shares issued (in shares)	375,299,980	374,952,693
Cronos Group, Inc. | Altria Group, Inc.
Derivative [Line Items]
Common stock, shares issued (in shares)	156,573,537
Ownership percentage (Whistler - less than)	42.00%		45.00%
Cronos Group, Inc. | Altria Group, Inc.
Derivative [Line Items]
Ownership percentage, if warrant exercised	52.00%
Altria Investment
Derivative [Line Items]
Maximum additional subscription percentage	10.00%
Derivative liability, additional subscription (in shares)	83,399,995
Altria Warrant
Derivative [Line Items]
Number of warrants issued | warrant	1
Exercise price (in dollars per share) | $ / shares	$ 19
Pre-emptive Rights
Derivative [Line Items]
Exercise price (in dollars per share) | $ / shares	$ 16.25
Exercise rights, minimum ownership percentage	20.00%

Derivative Liabilities - Schedu

Derivative Liabilities - Schedule of Reconciliation of Carrying Amounts (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Derivative Instruments [Roll Forward]
Beginning balance	$ 14,375	$ 163,410
Revaluation (gain) loss	(10,419)	116,874
Exercise of rights	0	(11,278)
Foreign exchange effect	143	3,294
Ending balance	4,099	272,300
Altria Warrant
Derivative Instruments [Roll Forward]
Beginning balance	13,720	138,858
Revaluation (gain) loss	(10,011)	92,964
Exercise of rights	0	0
Foreign exchange effect	136	2,834
Ending balance	3,845	234,656
Pre-emptive Rights
Derivative Instruments [Roll Forward]
Beginning balance	180	12,095
Revaluation (gain) loss	(115)	7,833
Exercise of rights	0	0
Foreign exchange effect	2	245
Ending balance	67	20,173
Top-up Rights
Derivative Instruments [Roll Forward]
Beginning balance	475	12,457
Revaluation (gain) loss	(293)	16,077
Exercise of rights	0	(11,278)
Foreign exchange effect	5	215
Ending balance	$ 187	$ 17,471

Derivative Liabilities - Sche_2

Derivative Liabilities - Schedule of Fair Values of Derivative Liabilities (Details)	3 Months Ended	12 Months Ended
	Mar. 31, 2022$ / shares	Dec. 31, 2021$ / shares
Altria Warrant | Share price at valuation date
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	4.85	4.98
Altria Warrant | Subscription price
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	19	19
Altria Warrant | Expected annualized volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	0.71	0.80
Altria Warrant | Expected dividend yield
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	0	0
Altria Warrant | Weighted Average | Weighted-average risk-free interest rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	0.0184	0.0079
Altria Warrant | Weighted Average | Weight-average expected life
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected life	11 months 8 days	1 year 2 months 4 days
Pre-emptive Rights | Share price at valuation date
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	4.85	4.98
Pre-emptive Rights | Subscription price
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	16.25	16.25
Pre-emptive Rights | Expected annualized volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	0.71	0.80
Pre-emptive Rights | Expected dividend yield
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	0	0
Pre-emptive Rights | Weighted Average | Weighted-average risk-free interest rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	0.0131	0.0039
Pre-emptive Rights | Weighted Average | Weight-average expected life
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected life	6 months	6 months
Top-up Rights | Share price at valuation date
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	4.85	4.98
Top-up Rights | Subscription price
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	16.25	16.25
Top-up Rights | Expected annualized volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	0.71	0.80
Top-up Rights | Expected dividend yield
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	0	0
Top-up Rights | Weighted Average | Weighted-average risk-free interest rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	0.0138	0.0050
Top-up Rights | Weighted Average | Weight-average expected life
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected life	9 months	9 months 18 days
Pre-emptive Rights and Top-up Rights | Minimum | Weighted-average risk-free interest rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	0.0060	0.0016
Pre-emptive Rights and Top-up Rights | Minimum | Weight-average expected life
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected life	3 months	3 months
Pre-emptive Rights and Top-up Rights | Maximum | Weighted-average risk-free interest rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	0.0228	0.0110
Pre-emptive Rights and Top-up Rights | Maximum | Weight-average expected life
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected life	3 years 6 months	3 years 9 months

Derivative Liabilities - Sche_3

Derivative Liabilities - Schedule of Sensitivity Analysis (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Altria Warrant
Sensitivity Analysis, Impact of 10 Percent Decrease (Increase) on Net Income (Loss) [Abstract]
Share price	$ 1,445	$ 3,970
Weighted-average expected life	1,114	2,971
Expected annualized volatility	1,930	5,402
Pre-emptive Rights
Sensitivity Analysis, Impact of 10 Percent Decrease (Increase) on Net Income (Loss) [Abstract]
Share price	34	80
Weighted-average expected life	65	171
Expected annualized volatility	41	96
Top-up Rights
Sensitivity Analysis, Impact of 10 Percent Decrease (Increase) on Net Income (Loss) [Abstract]
Share price	53	123
Weighted-average expected life	60	133
Expected annualized volatility	$ 67	$ 155

Restructuring - Narrative (Deta

Restructuring - Narrative (Details) - Realignment - USD ($) $ in Thousands	Mar. 31, 2022	Feb. 28, 2022
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges		$ 5,800
Restructuring costs incurred to date	$ 3,084
Anticipated capital expenditures	2,500
Facility Closing
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	$ 2,700

Restructuring - Costs by Segmen

Restructuring - Costs by Segment (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Restructuring Cost and Reserve [Line Items]
Restructuring costs	$ 3,084	$ 0
Realignment
Restructuring Cost and Reserve [Line Items]
Restructuring costs	3,084	0
Rest of World | Realignment
Restructuring Cost and Reserve [Line Items]
Restructuring costs	2,031	0
United States | Realignment
Restructuring Cost and Reserve [Line Items]
Restructuring costs	$ 1,053	$ 0

Restructuring - Restructuring A

Restructuring - Restructuring Activity (Details) - Realignment $ in Thousands	3 Months Ended
	Mar. 31, 2022USD ($)
Restructuring Reserve [Roll Forward]
Accrual as of December 31, 2021	$ 0
Year-to-date expense	3,084
Payments	(1,686)
Accrual as of March 31, 2022	1,398
Employee termination benefits
Restructuring Reserve [Roll Forward]
Accrual as of December 31, 2021	0
Year-to-date expense	2,503
Payments	(1,249)
Accrual as of March 31, 2022	1,254
Other restructuring costs
Restructuring Reserve [Roll Forward]
Accrual as of December 31, 2021	0
Year-to-date expense	581
Payments	(437)
Accrual as of March 31, 2022	$ 144

Share-based Payments - Summary

Share-based Payments - Summary of Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation	$ 3,686	$ 2,499
Employee termination benefits
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation	1,583
Stock options
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation	1,729	2,064
Restricted share units
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation	$ 1,957	$ 435

Share-based Payments - Stock Op

Share-based Payments - Stock Options Narrative (Details) - Stock options	3 Months Ended
	Mar. 31, 2022
2020 Omnibus Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period	10 years
Prior Option Plans
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period	7 years
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	5 years

Share-based Payments - Summar_2

Share-based Payments - Summary of the Changes in Options (Details) - $ / shares	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Weighted average exercise price
Balance at beginning of period (in dollars per share)	$ 7.75	$ 5.40	$ 5.40
Exercise of options (in dollars per share)	3.14	2.13
Cancellation, forfeiture and expiry of options (in dollars per share)	12.46	14.71
Balance at end of period (in dollars per share)	8.55	7.38	$ 7.75	$ 5.40
Weighted average exercise price of options exercisable (in dollars per share)	$ 7.96	$ 5.75
Number of options
Balance at beginning of period (in shares)	8,939,330	13,755,148	13,755,148
Exercise of options (in shares)	(1,356,875)	(5,230,550)
Cancellation, forfeiture and expiry of options (in shares)	(55,791)	(25,771)
Balance at end of period (in shares)	7,526,664	8,498,827	8,939,330	13,755,148
Exercisable (in shares)	4,654,574	4,896,820
Weighted-average remaining contractual term (years)
Outstanding	1 year 8 months 19 days	2 years 9 months 25 days	2 years 8 months 12 days	2 years 3 months 18 days
Exercisable	1 year 1 month 20 days	1 year 5 months 15 days

Share-based Payments - Schedule

Share-based Payments - Schedule of Stock Options Outstanding (Details) - shares	Mar. 31, 2022	Dec. 31, 2021	Mar. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options outstanding (in shares)	7,526,664	8,939,330	8,498,827	13,755,148
2020 Omnibus Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options outstanding (in shares)	2,900,000	2,900,000
2018 Stock Option Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options outstanding (in shares)	1,523,449	1,550,074
2015 Stock Option Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options outstanding (in shares)	3,103,215	4,489,256

Share-based Payments - Summar_3

Share-based Payments - Summary of Changes in RSUs (Details) - Restricted share units - $ / shares	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Weighted-average grant date fair value
Balance at beginning of period (in dollars per share)	$ 9.22	$ 7.66
Granted (in dollars per share)	3.52	13.27
Vested and issued (in dollars per share)	10.81
Cancellation and forfeitures (in dollars per share)	7.92
Balance at end of period (in dollars per share)	$ 4.74	$ 8.89
Number of awards
Balance at beginning of period (in shares)	1,225,870	948,357
Granted (in shares)	3,950,334	265,904
Vested and issued/liabilities settled (in shares)	(78,631)
Cancellation and forfeitures (in shares)	(55,479)
Balance at end of period (in shares)	5,042,094	1,214,261
Vesting period	3 years
Minimum
Number of awards
Cliff period	3 years
Maximum
Number of awards
Cliff period	5 years

Share-based Payments - Summar_4

Share-based Payments - Summary of DSU Activity (Details) - Deferred Share Units (DSUs) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Financial liability
Balance at beginning of period	$ 408	$ 577
(Gain) loss on revaluation	(66)	211
Balance at end of period	$ 342	$ 788
Number of awards
Balance at beginning of period (in shares)	104,442	83,293
Balance at end of period (in shares)	104,442	83,293

Share-based Payments - Summar_5

Share-based Payments - Summary of Changes in Warrants (Details) - Warrants	3 Months Ended
	Mar. 31, 2021$ / sharesshares
Weighted-average exercise price (C$)
Balance at beginning of period (in dollars per share) | $ / shares	$ 0.25
Exercise of warrants (in dollars per share) | $ / shares	0.25
Balance at end of period (in dollars per share) | $ / shares	$ 0.25
Number of awards
Balance at beginning of period (in shares) | shares	7,987,349
Exercise of warrants (in shares) | shares	(7,977,349)
Balance at end of period (in shares) | shares	10,000

Share-based Payments - Warrants

Share-based Payments - Warrants Narrative (Details) - shares	Mar. 31, 2021	Dec. 31, 2020
Warrants
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of warrants (in shares)	10,000	7,987,349

Earnings (Loss) Per Share - Sch

Earnings (Loss) Per Share - Schedule of Earnings (Loss) Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Basic and diluted loss per share computation
Net loss from continuing operations attributable to the shareholders of Cronos Group	$ (32,638)	$ (161,291)
Weighted-average number of common shares outstanding for computation for basic earnings per share (in shares)	375,022,724	363,012,740
Weighted-average number of common shares outstanding for computation for diluted earnings per share (in shares)	375,022,724	363,012,740
Basic loss from continuing operations per share (in dollars per share)	$ (0.09)	$ (0.44)
Diluted loss per share from continuing operations (in dollars per share)	$ (0.09)	$ (0.44)
Loss from discontinued operations attributable to the shareholders of Cronos Group	$ 0	$ (21)
Basic loss from discontinued operations per share (in dollars per share)	$ 0	$ 0
Diluted loss from discontinued operations per share (in dollars per share)	$ 0	$ 0
Total anti-dilutive securities (in shares)	118,224,080	136,945,023

Segment Information - Schedule

Segment Information - Schedule of Segment Data (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Segment Reporting Information [Line Items]
Net revenue	$ 25,033	$ 12,611
Share of loss from equity accounted investees	0	1,643
Total assets	1,371,001	1,881,282	$ 1,397,738
Depreciation and amortization	1,293	735
Loss from discontinued operations	0	21
Adjusted EBITDA	(18,900)	(36,574)
Purchase of property, plant and equipment, net	711	6,680
Operating Segments | United States
Segment Reporting Information [Line Items]
Net revenue	2,328	2,441
Share of loss from equity accounted investees		0
Total assets	441,064	252,449
Depreciation and amortization	96	71
Loss from discontinued operations		0
Adjusted EBITDA	(7,086)	(9,510)
Purchase of property, plant and equipment, net	0	80
Operating Segments | Rest of World
Segment Reporting Information [Line Items]
Net revenue	22,705	10,170
Share of loss from equity accounted investees		1,643
Total assets	283,182	394,442
Depreciation and amortization	1,197	664
Loss from discontinued operations		21
Adjusted EBITDA	(3,425)	(22,184)
Purchase of property, plant and equipment, net	711	6,600
Corporate
Segment Reporting Information [Line Items]
Net revenue	0	0
Share of loss from equity accounted investees		0
Total assets	646,755	1,234,391
Depreciation and amortization	0	0
Loss from discontinued operations		0
Adjusted EBITDA	(8,389)	(4,880)
Purchase of property, plant and equipment, net	0	0
Cannabis flower
Segment Reporting Information [Line Items]
Net revenue	18,625	9,434
Cannabis flower | Operating Segments | United States
Segment Reporting Information [Line Items]
Net revenue	0	0
Cannabis flower | Operating Segments | Rest of World
Segment Reporting Information [Line Items]
Net revenue	18,625	9,434
Cannabis flower | Corporate
Segment Reporting Information [Line Items]
Net revenue	0	0
Cannabis extracts
Segment Reporting Information [Line Items]
Net revenue	6,316	3,144
Cannabis extracts | Operating Segments | United States
Segment Reporting Information [Line Items]
Net revenue	2,328	2,441
Cannabis extracts | Operating Segments | Rest of World
Segment Reporting Information [Line Items]
Net revenue	3,988	703
Cannabis extracts | Corporate
Segment Reporting Information [Line Items]
Net revenue	0	0
Other
Segment Reporting Information [Line Items]
Net revenue	92	33
Other | Operating Segments | United States
Segment Reporting Information [Line Items]
Net revenue	0	0
Other | Operating Segments | Rest of World
Segment Reporting Information [Line Items]
Net revenue	92	33
Other | Corporate
Segment Reporting Information [Line Items]
Net revenue	$ 0	$ 0

Segment Information - Schedul_2

Segment Information - Schedule of Adjusted EBITDA (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Segment Reporting Information [Line Items]
Net loss	$ (32,653)	$ (161,625)
Interest income, net	(2,046)	(2,329)
Income tax expense	362	0
Share of loss from equity accounted investees	0	1,643
Impairment loss on long-lived assets	3,493	1,741
(Gain) loss on revaluation of derivative liabilities	(10,419)	116,874
Transaction costs		501
(Gain) loss on revaluation of financial instruments	(4,268)	200
Impairment loss on other investments	11,238	0
Foreign currency transaction loss	1,872	0
Other, net	(135)	16
Restructuring costs	3,084	0
Loss from discontinued operations	0	21
Share-based compensation	3,686	2,499
Financial statement review costs	4,062	2,005
Depreciation and amortization	2,824	1,880
Adjusted EBITDA	(18,900)	(36,574)
Operating Segments | United States
Segment Reporting Information [Line Items]
Net loss	(22,216)	(12,092)
Interest income, net	(29)	(3)
Income tax expense	0
Share of loss from equity accounted investees		0
Impairment loss on long-lived assets	0	1,741
(Gain) loss on revaluation of derivative liabilities	0	0
Transaction costs		0
(Gain) loss on revaluation of financial instruments	0	0
Impairment loss on other investments	11,238
Foreign currency transaction loss	0
Other, net	0	0
Restructuring costs	1,053
Loss from discontinued operations		0
Share-based compensation	2,436	745
Financial statement review costs	0	0
Depreciation and amortization	432	99
Adjusted EBITDA	(7,086)	(9,510)
Operating Segments | Rest of World
Segment Reporting Information [Line Items]
Net loss	2,014	(142,147)
Interest income, net	(2,017)	(2,326)
Income tax expense	362
Share of loss from equity accounted investees		1,643
Impairment loss on long-lived assets	3,493	0
(Gain) loss on revaluation of derivative liabilities	(10,419)	116,874
Transaction costs		0
(Gain) loss on revaluation of financial instruments	(4,268)	200
Impairment loss on other investments	0
Foreign currency transaction loss	1,872
Other, net	(135)	16
Restructuring costs	2,031
Loss from discontinued operations		21
Share-based compensation	1,250	1,754
Financial statement review costs	0	0
Depreciation and amortization	2,392	1,781
Adjusted EBITDA	(3,425)	(22,184)
Corporate
Segment Reporting Information [Line Items]
Net loss	(12,451)	(7,386)
Interest income, net	0	0
Income tax expense	0
Share of loss from equity accounted investees		0
Impairment loss on long-lived assets	0	0
(Gain) loss on revaluation of derivative liabilities	0	0
Transaction costs		501
(Gain) loss on revaluation of financial instruments	0	0
Impairment loss on other investments	0
Foreign currency transaction loss	0
Other, net	0	0
Restructuring costs	0
Loss from discontinued operations		0
Share-based compensation	0	0
Financial statement review costs	4,062	2,005
Depreciation and amortization	0	0
Adjusted EBITDA	$ (8,389)	$ (4,880)

Segment Information - Schedul_3

Segment Information - Schedule of Revenue from External Customers by Geographic Areas (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenue	$ 25,033	$ 12,611
Canada
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenue	13,576	7,582
Israel
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenue	9,128	2,518
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenue	2,329	2,441
Other countries
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenue	$ 0	$ 70

Segment Information - Schedul_4

Segment Information - Schedule of Long-lived Assets by Geographic Areas (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	$ 71,828	$ 74,070
Canada
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	47,717	49,117
Israel
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	23,823	24,473
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	$ 288	$ 480

Commitments and Contingencies (

Commitments and Contingencies (Details) - Pending Litigation $ in Millions	Jun. 16, 2020CAD ($)	Mar. 12, 2020shareholdercomplaint
Litigation Relating to Marketing, Distribution and Sale of Products
Loss Contingencies [Line Items]
Damages sought	$ 500
Punitive damages sought	$ 5
U.S. District Court of Eastern District of New York Vs. Cronos
Loss Contingencies [Line Items]
Number of alleged shareholders | shareholder		2
Number of putative class action complaints | complaint		2

Financial Instruments - Schedul

Financial Instruments - Schedule of Fair Value of Assets Measured on Recurring Basis (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other investments	$ 12,607	$ 8,000
Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	861,535	886,973
Short-term investments	119,933	117,684
Derivative liabilities	4,099	14,375
Fair Value, Recurring | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	861,535	886,973
Short-term investments	119,933	117,684
Other investments	12,607	8,000
Derivative liabilities	0	0
Fair Value, Recurring | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	0	0
Short-term investments	0	0
Other investments	0	0
Derivative liabilities	0	0
Fair Value, Recurring | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	0	0
Short-term investments	0	0
Other investments	0	0
Derivative liabilities	$ 4,099	$ 14,375

Impairment Loss on Long-lived_2

Impairment Loss on Long-lived Assets (Details) ft² in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2022USD ($)ft²	Mar. 31, 2021USD ($)ft²
Impaired Long-Lived Assets Held and Used [Line Items]
Impairment loss on long-lived assets	$ 3,493	$ 1,741
Lease impairment, area of land(in sqft) | ft²	29	6
Impairment charge on the de-recognition of the right-of-use asset		$ 702
Leasehold Improvements and Other Office Equipment
Impaired Long-Lived Assets Held and Used [Line Items]
Impairment of intangible assets, finite-lived	$ 1,507
Leasehold improvements
Impaired Long-Lived Assets Held and Used [Line Items]
Impairment loss on long-lived assets	$ 1,986	$ 1,039

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Mar. 08, 2019
Cronos Group, Inc. | Altria Group, Inc.
Related Party Transaction [Line Items]
Ownership interest	42.00%			45.00%
Cronos GrowCo
Related Party Transaction [Line Items]
Ownership interest	50.00%
Consulting Services Arrangement | Altria Pinnacle
Related Party Transaction [Line Items]
Consulting fees	$ 28,000	$ 8,000
Amounts payable	13,000		$ 0
Cannabis Purchases | Cronos GrowCo
Related Party Transaction [Line Items]
Amounts payable	0		$ 82,000
Purchases	$ 3,218,000	$ 0